1. Neuroscience

Paradoxical neuronal hyperexcitability in a mouse model of mitochondrial pyruvate import deficiency

  1. Andres De La Rossa
  2. Marine H Laporte  Is a corresponding author
  3. Simone Astori
  4. Thomas Marissal
  5. Sylvie Montessuit
  6. Preethi Sheshadri
  7. Eva Ramos-Fernández
  8. Pablo Mendez
  9. Abbas Khani
  10. Charles Quairiaux
  11. Eric B Taylor
  12. Jared Rutter
  13. José Manuel Nunes
  14. Alan Carleton
  15. Michael R Duchen
  16. Carmen Sandi  Is a corresponding author
  17. Jean-Claude Martinou  Is a corresponding author
  1. Department of Cell Biology, University of Geneva, Switzerland
  2. Laboratory of Behavioral Genetics, Ecole Polytechnique Fédérale de Lausanne, Switzerland
  3. Institut de Neurobiologie de la Méditerranée (INMED), Université d'Aix- Marseille, France
  4. Department of Basic Neuroscience, University of Geneva., Switzerland
  5. Department of Cell and Developmental Biology, University College London, United Kingdom
  6. Cajal Institute, Spain
  7. Department of Biochemistry and Fraternal Order of Eagles Diabetes Research Center, Carver College of Medicine, University of Iowa, United States
  8. Howard Hughes Medical Institute and Department of Biochemistry, University of Utah School of Medicine, United States
  9. Department of Genetic and Evolution, University of Geneva, Switzerland
https://doi.org/10.7554/eLife.72595
Share this article
Cite this article
  1. Andres De La Rossa
  2. Marine H Laporte
  3. Simone Astori
  4. Thomas Marissal
  5. Sylvie Montessuit
  6. Preethi Sheshadri
  7. Eva Ramos-Fernández
  8. Pablo Mendez
  9. Abbas Khani
  10. Charles Quairiaux
  11. Eric B Taylor
  12. Jared Rutter
  13. José Manuel Nunes
  14. Alan Carleton
  15. Michael R Duchen
  16. Carmen Sandi
  17. Jean-Claude Martinou
(2022)
Paradoxical neuronal hyperexcitability in a mouse model of mitochondrial pyruvate import deficiency
eLife 11:e72595.
https://doi.org/10.7554/eLife.72595
  2. Download BibTeX
  3. Download .RIS

Abstract

Neuronal excitation imposes a high demand of ATP in neurons. Most of the ATP derives primarily from pyruvate-mediated oxidative phosphorylation, a process that relies on import of pyruvate into mitochondria occuring exclusively via the mitochondrial pyruvate carrier (MPC). To investigate whether deficient oxidative phosphorylation impacts neuron excitability, we generated a mouse strain carrying a conditional deletion of MPC1, an essential subunit of the MPC, specifically in adult glutamatergic neurons. We found that, despite decreased levels of oxidative phosphorylation and decreased mitochondrial membrane potential in these excitatory neurons, mice were normal at rest. Surprisingly, in response to mild inhibition of GABA mediated synaptic activity, they rapidly developed severe seizures and died, whereas under similar conditions the behavior of control mice remained unchanged. We report that neurons with a deficient MPC were intrinsically hyperexcitable as a consequence of impaired calcium homeostasis, which reduced M-type potassium channel activity. Provision of ketone bodies restored energy status, calcium homeostasis and M-channel activity and attenuated seizures in animals fed a ketogenic diet. Our results provide an explanation for the seizures that frequently accompany a large number of neuropathologies, including cerebral ischemia and diverse mitochondriopathies, in which neurons experience an energy deficit.

Editor's evaluation

This paper finds that conditional deletion in excitatory neurons of the only known pathway allowing the uptake of pyruvate into mitochondria, the mitochondrial pyruvate carrier, is tolerated in mice but produces hyperexcitability. The mice are more susceptible to epileptic seizures when inhibitory neurotransmission is impaired pharmacologically. Convincing evidence is presented that this hyperexcitability is due to decreased activity of Kv7.2/7.3 channels, secondary to dysregulation of cellular calcium handling.

https://doi.org/10.7554/eLife.72595.sa0

Introduction

During neuronal activity, the energy demand imposed by neuronal excitation is mainly met by glucose, which is oxidized through glycolysis and oxidative phosphorylation (OXPHOS) to produce ATP (Ashrafi and Ryan, 2017). Oxidation of glucose starts in the cytosol and generates pyruvate, which, in turn, is transported into mitochondria through the mitochondrial pyruvate carrier (MPC) (Bricker et al., 2012; Herzig et al., 2012), where it fuels the TCA cycle and boosts OXPHOS. In neurons, pyruvate can also be generated through oxidation of astrocyte-derived lactate by the lactate dehydrogenase (Pellerin et al., 2007).

Besides energy production, glucose and pyruvate oxidation via the TCA cycle is also required for the synthesis of essential molecules, including the neurotransmitters glutamate and γ−aminobutyric acid (GABA). Therefore ATP production and neurotransmitter release are tightly linked to glucose and pyruvate metabolism. Accordingly, genetic pathologies linked to impaired glucose or pyruvate oxidation, such as mutations in the glucose transporter 1 (GLUT1) (Brockmann et al., 2001), pyruvate dehydrogenase (PDH) (Ostergaard et al., 2009), MPC (Brivet et al., 2003; Oonthonpan et al., 2019), or complexes of the respiratory chain (Diaz et al., 2011) result in severe synaptic dysfunction (Beck and Yaari, 2008). Not surprisingly, these diseases are associated with brain hypoactivity, although paradoxically they can be accompanied by neuronal hyperexcitability and behavioral seizures of varying severity. Indeed, this is paradoxical because it is generally thought that neuronal excitation imposes a high demand of OXPHOS-derived ATP in neurons. This raises the question of how these paroxysmal, ATP consuming events can occur in patients despite a global brain energy deficit.

A few years ago, the molecular identity of the MPC was revealed (Bricker et al., 2012; Herzig et al., 2012). The MPC is a heterodimer composed of two subunits, MPC1 and MPC2, inserted into the inner mitochondrial membrane (Bricker et al., 2012; Herzig et al., 2012). Deletion of MPC1 and MPC2 was sufficient to inactivate the carrier activity and its constitutive inactivation in the mouse caused embryonic lethality at E12 (Vanderperre et al., 2016; Vigueira et al., 2014). Interestingly, providing ketone bodies, which directly feed the TCA cycle with acetyl-CoA and boost OXPHOS, to the pregnant females allowed the embryos to survive until birth (Vanderperre et al., 2016).

Here, we hypothesized that downregulation of the MPC in neurons from adult mice would have a major impact on neuronal function and would result in decreased brain activity given the importance of the MPC in providing the TCA cycle with one of its main substrates. To test this hypothesis, we inactivated the MPC in adult mice, specifically in CamKIIα-expressing neurons (i.e. excitatory, glutamatergic neurons). We found that, under resting conditions, mice lacking MPC1 in these excitatory neurons were indistinguishable from control mice in their general exploratory, social and stress-coping behaviors. In response to inhibition of GABA mediated synaptic activity they developed far more severe seizures than controls. This phenotype was due to an intrinsic membrane hyperexcitability of MPC1-deficient glutamatergic neurons, which resulted from a calcium-mediated decrease in M-type K+ channel activity. Strikingly, the hyperexcitability phenotype was reversed when the animals were maintained on a ketogenic diet.

Results

MPC-deficient cortical neurons display decreased pyruvate-mediated oxidative phosphorylation in vitro

To assess the role of the mitochondrial pyruvate carrier (MPC) in neuronal OXPHOS, we first used primary cultures of cortical neurons largely depleted of astrocytes (Figure 1—figure supplement 1A) and either RNA interference or pharmacological reagents to downregulate their MPC activity. To this end, two different shRNAs targeting MPC1 and three different pharmacological inhibitors of the carrier, Zaprinast (Du et al., 2013), Rosiglitazone (Divakaruni et al., 2013), and UK5099 (Halestrap, 1975) were used. Expression of either of the two shRNAs produced a significant reduction in MPC1 and MPC2 protein levels (the latter being unstable in the absence of MPC1) (Figure 1—figure supplement 1B, C). Both genetic and pharmacological impairment of MPC activity resulted in decreased pyruvate-driven basal and maximal oxygen consumption rates (OCR) (Figure 1A, Figure 1—figure supplement 1D) and decreased mitochondrial ATP production (Figure 1B), which is consistent with previously published results (Divakaruni et al., 2017; Grenell et al., 2019). Furthermore, mitochondrial membrane potential, measured using mitotracker and TMRE was significantly reduced in MPC-deficient neurons (Figure 1C , F). This was associated with an increased extracellular acidification rate (Figure 1—figure supplement 1E) and increased glucose uptake, which was measured using the 2-NBDG import assay (Figure 1—figure supplement 1F), two hallmarks of aerobic glycolysis.

Figure 1 with 1 supplement see all
Download asset Open asset
MPC-deficient neurons display defects in mitochondrial respiration and membrane potential.

(A) Profile and quantification of oxygen consumption rates (OCR) cortical neurons expressing either shCtrl, or shMPC1_1 and shMPC1_2 for 7 days, or in the presence of Zaprinast (5 μM, 1 hr). Data were obtained using the Seahorse XF analyzer. Assays were performed in the presence of pyruvate (5 mM) and glucose (5 mM) as carbon sources. Quantification of basal OCR is expressed as ratio of ShCtrl. N = 10,7,9,7 and 2 independent experiments. N = 33,11,25 and 6 independent experiments. One-way ANOVA + Tukey’s post-hoc test (shCtrl vs Zaprinast p = 0.0001, shCtrl vs shMPC1_1 p = 0.0001, shCtrl vs shMPC1_2 p = 0.0013). (B) ATP content in MPC-deficient cortical neurons treated with either shCtrl, Zaprinast or shMPC1_1 and shMPC1_2. fCCP (4 μM) treatment reveals the non-mitochondrial ATP. N = 10,7,9,7 and 2 independent experiments. One-way ANOVA + Tukey’s post-hoc test (shCtrl vs Zaprinast p = 0.0006, shCtrl vs shMPC1_1 p = 0.0223, shCtrl vs shMPC1_2 p = 0.0242, shCtrl vs fCCP p = 0.0001). (C) Mitochondrial membrane potential of MPC-deficient cortical neurons. Neurons were incubated with Mitotracker red (MtR) (1 μM) prior fixation, immunostained for βIII tubulin (neuron) and TOM20 (mitochondria). Quantification of Mitotracker red fluorescence in each βIII tubulin-positive cell (red) was reported to TOM20 signal (green). N = 15 neurons from three independent experiments. Unpaired t test (shCtrl vs shMPC1 p = 0.0001). (D) Profile and quantification of oxygen consumption rates (OCR) in cortical neurons expressing shCtrl or shMPC1_1 for 7 days. Data were obtained using the Seahorse XF analyzer. Assays were performed in the presence of pyruvate (5 mM) and glucose (5 mM) as carbon sources + 10 mM βHB when indicated. Quantification of basal OCR is expressed as ratio of control condition shCtrl. N = 12 independent experiment. One-way ANOVA + Holm Sidak’s post-hoc test (shCtrl vs shMPC1 p = 0.0001, shMPC1 vs shMPC1+βHB p = 0.0002). (E) ATP content in MPC-deficient cortical neurons treated with shCtrl or shMPC1 in presence or absence of 10 mM βHB. fCCP (4 μM) treatment reveals the non-mitochondrial ATP. N = 10, 9, 10, 9 independent experiments. One-way ANOVA + Holm Sidak’s post-hoc test (shCtrl vs shMPC1 p = 0.0145, shMPC1 vs shMPC1+βHB p = 0.0143, shCtrl vs fCCP p = 0.0001). (F) Cortical neurons were incubated with TMRE (50 nM) +/- βHB (10 mM) for 30 min and recorded by live microscopy. Neurons were incubated with DMSO or Zaprinast (5 μM) 2.5 min after the beginning of the acquisition and recorded for 5 min prior fCCP injection. N = 15 independent experiments. One-way ANOVA + Holm Sidak’s post-hoc test (shCtrl vs Zaprinast p = 0.0028, Zaprinast vs Zaprinast+βHB P = 0.0008).

We have previously reported that ketone bodies can restore normal OXPHOS in MPC-deficient murine embryonic fibroblasts (Vanderperre et al., 2016). Consistent with this, we found here that addition of the ketone body β-hydroxybutyrate (βHB) (10 mM) to the culture medium rescued all observed defective functionalities in MPC-deficient neurons, including oxygen consumption, ATP production, membrane potential (Figure 1D-F) and both extracellular acidification rate and glucose uptake (Figure 1—figure supplement 1G, H). Thus, we conclude that MPC-deficient neurons display low pyruvate-mediated oxidative phosphorylation and high aerobic glycolysis, both reversed with βHB.

Generation of mice with inducible MPC1 gene deletion in adult glutamatergic neurons

Based on the results described above, and because neural excitation requires massive levels of ATP, we hypothesized that loss of MPC activity would reduce excitability especially in glutamatergic neurons that are high energy consumers. To test this hypothesis, we generated a mouse strain with an inducible deletion of the MPC1 gene, specifically in the Ca2+-calmodulin kinase IIα (CamKIIα)-expressing neurons, found predominantly in the hippocampus and cortex (Wang et al., 2013). We crossed Mpc1flox/flox mice with the commercially available CamkIIaCreERT2 mice (Figure 2A). Induction of Cre activity by injection of Tamoxifen for five consecutive days resulted in deletion of MPC1 FLOXed alleles in the CamKIIα-expressing adult neurons (Figure 2A). Hereafter, we refer to these mice as neuro-MPC1-KO. In situ immunofluorescence analyses showed a decrease in neuronal MPC1 immunostaining in various layers of the cortex of neuro-MPC1-KO mice (Figure 2B). Western blot analysis of whole cortex, synaptosomes and mitochondria showed a significant decrease of both MPC1 and MPC2 in neuro-MPC1-KO mice compared to neuro-MPC1-WT mice (Figure 2C). Consistent with the results obtained in cultured neurons, we found that synaptosomes prepared from the cortex of neuro-MPC1-KO mice displayed lower oxygen consumption and imported higher amounts of glucose compared to synaptosomes from neuro-MPC1-WT mice (Figure 2—figure supplement 1A, B). Importantly, the lack of MPC1 did not affect the neuronal cell survival quantified either by counting the total number of cells, or by the number of apoptotic (TUNEL positive) cells (Figure 2—figure supplement 1C, D). At adulthood, both genotypes displayed similar body weight and fat mass composition (Figure 2—figure supplement 1E, F). At the behavioral level, adult neuro-MPC1-KO mice showed a tendency toward lower anxiety-like behaviors, but no difference in general locomotion, sociability or stress-coping behaviors (Figure 2—figure supplement 1G, H).

Figure 2 with 1 supplement see all
Download asset Open asset
Generation of mice with an inducible deletion of the MPC1 gene in adult glutamatergic neurons.

(A) Strategies used to generate CamKIIaCreERT2-Mpc1flox/flox mice. Upon Tamoxifen injection, expression of the Cre recombinase in CamKIIα glutamatergic neurons drives deletion of the MPC1 gene. These mice are referred to as neuro-MPC1-KO or neuro-MPC1-WT when they are Cre- (1. Glutamatergic neuron; 2. Astrocytes; 3. Inhibitory neuron). (B) Immunostaining of MPC1 (red) in cortical sections from neuro-MPC1-WT and neuro-MPC1-KO mice (scale bar: 100 μm). (C) Western blot analysis of whole cortex, synaptosome lysates and heavy organelles (mainly mitochondria), obtained from brains of neuro-MPC1-WT and neuro-MPC1-KO mice using neuronal (Synaptophysin, tyrosine hydroxylase, CamKIIα) and astroglial markers (GFAP) as well as mitochondrial markers (MPC1, MPC2 and VDAC). Note that synaptosomes are enriched for CamKIIα, a marker of excitatory neurons. Quantification (right panel) shows that except for MPC1 and MPC2, the content of these markers is similar in WT and KO preparations. N = 6 independent neuro-MPC1-WT and neuro-MPC1-KO mice. Mann-Whitney test ((6) neuro-MPC1-WT vs neuro-MPC1-KO p = 0.0286, (7) neuro-MPC1-WT vs neuro-MPC1-KO p = 0.0152).

These data indicate that, under resting conditions, the excitatory neurons in most adult mice have the ability to bypass the MPC to meet their metabolic demands.

Neuro-MPC1-KO mice are highly sensitive to pro-convulsant drugs and develop acute epileptic-like seizures

The output activity of a neuron results from the balance between the excitatory and the inhibitory inputs it receives. Perturbation of this delicate balance can lead to severe seizures as a result of exacerbated, uncontrolled neuronal firing. To test whether OXPHOS-deficient excitatory neurons could sustain intense neuronal firing, we challenged neuro-MPC1-KO adult mice, with either pentylenetetrazole (PTZ), a GABA receptor antagonist, or kainic acid, an activator of glutamate receptors. We used the PTZ kindling protocol described previously (Dhir, 2012), in which a sub-convulsant dose (35 mg/kg) of PTZ is injected intraperitoneally (ip) once every 2 days on a period of 15 days (Figure 3A). Phenotypic scoring after each PTZ injection in neuro-MPC1-WT mice showed a progressive sensitization (kindling) starting with hypoactivity after the first injection (scored as 1); a few brief and transient muscle contractions (jerks, scored as 2) or appearance of tail rigidity (Straub’s tail, scored as 3) following the second or third injection; and convulsive status epilepticus (scored as 6) after the 6th or 7th injection (Figure 3A, B). In contrast, all neuro-MPC1-KO mice developed severe, prolonged seizures (score 6) within 10 min of the first PTZ injection (Figure 3B) and all died during seizures within the next three PTZ injections (Figure 3—figure supplement 1A). When mice were injected with 20 mg/kg kainic acid intraperitoneally, a similar hypersensitivity (score 6) was observed in neuro-MPC1-KO mice indicating that this sensitivity was not restricted to PTZ (Figure 3—figure supplement 1B).

In a parallel series of experiments, and in order to assess the specificity of our results to excitatory neurons, we investigated the effects of PTZ in mice in which MPC1 was deleted in adult astrocytes (hereafter termed astro-MPC1-KO mice) (Figure 3—figure supplement 1C-E). In contrast to neuro-MPC1-KO mice, astro-MPC1-KO mice showed the same response as control animals following PTZ injection (Figure 3—figure supplement 1F-G), indicating that the phenotype observed in neuro-MPC1-KO mice is linked to the deletion of MPC1 in excitatory neurons.

To characterize the seizure symptoms in more detail, we recorded the electrical activity in the brains of neuro-MPC1-WT and neuro-MPC1-KO mice by electroencephalogram (EEG) following a single injection of PTZ (Figure 3C). In neuro-MPC1-KO mice, rhythmic EEG patterns emerged within 5–10 min after PTZ injection, invading all electrodes (Figure 3C). These electrical patterns coincided with the occurrence of behavioral manifestations of seizures, that is tonic-clonic movements. Rapidly thereafter, large spike and wave discharges developed, again invading all surface electrodes and coinciding with numerous fast ripples (Figure 3C, inset). Such EEG patterns are characteristic of seizure episodes in humans and were not observed in the PTZ-injected neuro-MPC1-WT mice. These data indicate that neuro-MPC1-KO mice develop an epilepsy-like phenotype following administration of a single sub-convulsant dose of PTZ.

We also tested whether we could reproduce the seizure phenotype using hippocampal organotypic cultures from CamkIIaCreERT2-Mpc1flox/flox mice exposed to PTZ, combined with calcium imaging. Individual neurons in hippocampal slices from both WT and KO mice exhibited spontaneous calcium activity throughout the duration of the recordings (Figure 3D, E and Video 1, Video 2) although, interestingly, the frequency of calcium events, as well as the number of co-activation events (i.e. neuronal synchronizations above chance levels) generated in MPC1-deficient neurons were significantly higher than those generated in MPC1-WT neurons (Figure 3F, G). In contrast, neither the amplitude nor the duration of the discharges was modified (Figure 3H, I). These results suggest that neuro-MPC1-KO neurons are more active and are more often recruited into synchronized patterns associated with the epileptic activity.

Video 1
Download asset
Spontaneous calcium activity in neuro-MPC1-WT hippocampal slices following PTZ addition.
Video 2
Download asset
Spontaneous calcium activity in neuro-MPC1-KO hippocampal slices following PTZ addition.
Figure 3 with 1 supplement see all
Download asset Open asset
Neuro-MPC1-KO mice are highly sensitive to pro-convulsant drugs and develop acute epileptic-like seizures.

(A) Schematic description of the PTZ kindling protocol. (B) Seizure severity scores reflecting the different clinical symptoms as indicated, obtained for neuro-MPC1-WT or neuro-MPC1-KO. N = 8 independent neuro-MPC1-WT and neuro-MPC1-KO mice. Two way ANOVA (F(7,70)=19, p = 0.0001). (C) Illustration of the recording setups in awake mice indicating the position of surface EEG electrodes and representative example of a seizure recorded in a neuro-MPC1-KO mouse after injection of 35 mg/kg PTZ during surface EEG recordings. The inset shows an example of fast ripples generated during an ictal epileptic discharge. (D–I) GCaMP6S calcium imaging of the CA1 area from hippocampal slices in the presence of Carbachol (50 µM) and PTZ (2 mM). Slices were prepared from WT animals (top, black) or from KO animals with no pre-treatment (bottom, red). (D) Ca2+ sweeps recorded in four representative GCaMP6S-expressing neurons. (E) Raster plots of Ca2+ transient onsets extracted from all recorded neurons in a given slice. (F) Cumulative distribution of the frequency of the calcium events in all the recorded neurons. N = 7, 12 independent experiments. Kolmogorov-Smirnov test (WT vs KO p = 0.0001). (G) Cumulative distribution of the occurrence of neuronal co-activations exceeding chance levels as a function of time N = 7, 12 independent experiments. Kolmogorov-Smirnov test (WT vs KO p = 0.0344). Amplitude (H), and duration (I) of the calcium events recorded in all neurons of the hippocampus. N = 7, 12 independent experiments. Mann-Whitney test (Amplitude: WT vs KO p = 0.5918; Duration: WT vs KO p = 0.9182).

Inhibition of PTZ-induced seizures in neuro-MPC1-KO mice by the ketogenic diet

The ketogenic diet (KD) has been reported to decrease seizures in patients with pharmacologically refractory epilepsy (Carroll et al., 2019). Ketone bodies, mainly generated by the liver during fasting and hypoglycaemia, are used by neurons to provide the TCA cycle with acetyl-CoA, normally provided by pyruvate dehydrogenase-mediated oxidation of pyruvate. Thus, ketone bodies ensure that oxidative phosphorylation and ATP production is maintained in neurons in conditions of glucose starvation. We tested whether a ketogenic diet could prevent PTZ-induced seizures in neuro-MPC1-KO mice. As previously reported (Wirrell et al., 2018), we found that the KD produces a decrease in glycaemia and an increase in the blood level of 3-β-hydroxy-butyrate (βHB), one of the three major ketone bodies generated by the liver (Figure 4—figure supplement 1A, B). In addition, we found that mice fed on the KD for 1 week were completely resistant to PTZ injection (Figure 4A). Supplementing the drinking water with 1% βHB was sufficient to prevent PTZ-induced seizures (Figure 4B). Similarly, ip administration of βHB (1 g/Kg) 15 min before PTZ injection, or starvation overnight, both of which conditions led to increased βHB blood levels (Figure 4—figure supplement 1C-E), significantly reduced the PTZ-induced clinical score of neuro-MPC1-KO mice (Figure 4B, C). Similarly, supplementing the drinking water with 1% acetoacetate, another type of ketone body, reduced PTZ-induced seizures in neuro-MPC1-mice (Figure 4D). These results indicate that the phenotype displayed by the neuro-MPC1-KO mice is mainly metabolic in origin and is unlikely to be the consequence of neuronal network remodeling.

Figure 4 with 1 supplement see all
Download asset Open asset
Ketogenic diet prevents the epileptic phenotype of neuro-MPC1-KO mice.

(A) Effect of the ketogenic diet (KD) on PTZ-induced seizure. All neuro-MPC1-KO mice were maintained on the Standard (SD) or ketogenic (KD) diet for 7 days prior to challenge with a single dose of PTZ. Clinical scores were assessed directly following injection. N = 7 independent neuro-MPC1-KO mice. Mann-Whitney (neuro-MPC1-KO SD vs neuro-MPC1-KO KD p = 0.0008). (B) Effects 1% βHB in the drinking water for 7 days, overnight fasting or ip injection of βHB 15 min before administration of PTZ into neuro-MPC1-KO mice. N = 4 independent neuro-MPC1-KO mice. One-way ANOVA + Holm Sidak’s post-hoc test (Vehicle vs all conditions p = 0.0001). (C) Effect of βHB on PTZ-induced seizure: mice were injected ip with 1 g/kg βHB, 15 min before each PTZ injection and scored for clinical symptoms. N = 6 independent mice. Two-way ANOVA + Holm Sidak’s post-hoc test (F(10, 75) = 8, Neuro-MPC1-WT vs neuro-MPC1-KO, neuro-MPC1-KO vs neuro-MPC1-KO + βHB p = 0.0001). (D) Effect of acetoacetate (1% in drinking water) for 7 days on PTZ-induced seizures. Clinical scores were assessed directly following injection. N = 5 and 6 mice for vehicle or acetoacetate IP injected mice, respectively. Mann-Whitney (neuro-MPC1-KO vehicle vs neuro-MPC1-KO Acetoacetate p = 0.0022).

MPC1-deficient neurons display intrinsic hyperexcitability, which is prevented by ketone bodies

To investigate the cellular mechanisms that might mediate the sensitivity of neuro-MPC1-KO mice to pro-convulsant drugs, we examined the electrophysiological properties of MPC1-deficient neurons. To this end, we performed whole-cell patch clamp recordings in acute hippocampal slices from neuro-MPC1-KO mice and their neuro-MPC1-WT littermates. CA1 pyramidal cells from neuro-MPC1-KO mice exhibited higher discharge frequency compared to neurons from neuro-MPC1-WT mice when firing was elicited by somatic injections of current ramps of increasing amplitude (Figure 5A, B). Neurons from neuro-MPC1-KO mice required less current injection (rheobase, Figure 5C) to reach the firing threshold, which was more hyperpolarized when compared to neuro-MPC1-WT cells (Figure 5D). Similarly, MPC1-KO neurons displayed higher firing when depolarization was induced with squared current pulses (Figure 5—figure supplement 1A, B).

Figure 5 with 1 supplement see all
Download asset Open asset
MPC1 deletion increases intrinsic excitability in CA1 pyramidal cells.

(A) Example voltage responses elicited in CA1 pyramidal cells from wild-type (WT) and neuro-MPC1-KO (KO) by injection of current ramps (protocol at the bottom, only three of six ramps displayed). (B) Frequency-current (F–I) relationship of action potential discharges, indicating higher spiking frequency in KO cells (Two-way ANOVA, F(1, 156) 33.43, p < 0.0001). (C) The rheobase was reduced in KO cells (Mann-Whitney test, U = 53.5, p = 0.0406). (D) KO cells exhibited more hyperpolarized threshold potential (unpaired t test, t = 2.856, p = 0.0084). (E) Example traces showing lack of significant changes in WT cell firing after bath application of the ketone body β-hydroxybutyrate (βHB, 2 mM, > 20 min exposure). (F) Average firing frequency elicited by the 3rd ramp of current injections in WT cells in control condition (5 min after whole-cell establishment) and after 20 min of either no drug exposure or βHB application (no drug: paired t test, t = 0.664, p = 0.5362; βHB: paired t test, t = 2.1, p = 0.0804). (G), (H) Example traces and summary graphs indicating significant reduction in KO cell firing after βHB application (no drug: paired t test, t = 0.4691, p = 0.6634; βHB: paired t test, t = 5.339, p = 0.0005). (I) Example traces of cell firing in control and after bath application of XE991 (10 µM) in WT and KO neurons. (J) Average firing frequency elicited by the 2nd ramp of current injections in control and after XE991 application, indicating increased excitability in WT cells (paired t test, t = 3.735, p = 0.0057). XE991 was ineffective in KO cells, in which subsequent application of βHB also failed to modulate excitability (One-way ANOVA, F(1.69, 11.89) = 4.76, p = 0.0347, Holm-Sidak’s multiple comparison p > 0.05). (K) XE991 significantly reduced the rheobase of WT cells (paired t test, t = 11, p < 0.001), but not of KO cells, in which subsequent βHB application was also ineffective (One-way ANOVA, F(1.785, 12.5) = 2.99, p = 0.091). (L) XE991 induced a shift in the threshold potential of WT cells (paired t test, t = 6.001, p = 0.0003), but did not affect KO cells, in which subsequent βHB application was also ineffective (One-way ANOVA, F(1.812, 12.68) = 1.78, p = 0.209). (M) Example traces of KO cell firing elicited by a current ramp (300 pA max amplitude, APs are trimmed) in control and after βHB exposure, with expanded portion at the bottom indicating mAHP measurement. N) Summary graph of mAHP values in WT and KO cells in control and after βHB exposure, indicating significant increase in KO (unpaired t test, t = 2.89, p = 0.0179. (O) Example traces of KO cell firing before and after application of retigabine (10 µM), and subsequent βHB superfusion (2 mM). (P) F-I relationships in KO cells, indicating reduced spiking frequency after retigabine application, with no additional effect of βHB (Two-way repeated measures ANOVA, F(2, 48) = 89.15, p < 0.0001).

Next, we asked whether ketone bodies, which as shown in Figure 4 prevent PTZ-induced seizures, could modulate neuronal excitability and restore normal cell discharges in neuro-MPC1-KO mice. For these experiments, we first recorded action potential firing under control conditions, and then perfused the slices with βHB (2 mM, > 20 min exposure) (Ma et al., 2007). As shown in Figure 5, whereas cell firing was unaltered in neuro-MPC1-WT cells (Figure 5E, F), βHB reduced excitability in pyramidal cells from the neuro-MPC1-KO mice (Figure 5G, H). Control experiments showed that cell excitability from both genotypes was unchanged during prolonged recordings (Figure 5F, H), confirming that the change in neuro-MPC1-KO firing was not due to a rundown in cellular excitability caused by, for example, cell dialysis.

Taken together, these results indicate that ketone bodies reduce the intrinsic hyperexcitability of glutamatergic cells from neuro-MPC1-KO mice, providing a plausible explanation for the protective effect of the KD against PTZ-induced seizures.

MPC1-deficient neurons display altered M-type potassium channel activation, which is corrected by ß-hydroxybutyrate

To gain insight into the mechanisms governing neuronal hyperexcitability, we analysed the cellular passive properties and action potential characteristics of all recordings performed in cells from neuro-MPC1-KO and neuro-MPC1-WT mice (Figure 5—figure supplement 1C-K). The reduction in rheobase and the shift in threshold potential induced by MPC1 deletion were accompanied by several changes in passive and active membrane properties governing cell excitability, including a significant increase in the input resistance (Ri) and in the voltage response to a depolarizing current injection (depolsub), along with a marginally significant reduction in HCN channel-mediated sag (Figure 5—figure supplement 1C-I). The fast afterhyperpolarization (fAHP) accompanying action potentials was not altered, ruling out a major contribution of BK channels (Figure 5—figure supplement 1J). However, the medium afterhyperpolarization (mAHP), measured as the negative peak of the voltage deflection at the offset of the depolarizing ramps was significantly reduced in cells from neuro-MPC1-KO mice (Figure 5—figure supplement 1K). In CA1 pyramidal cells, mAHP is primarily mediated by the activation KCNQ2/3 (Kv7.2 and Kv7.3) channels, which generate an M-type K+ conductance regulating intrinsic excitability and synaptic integration (Gu et al., 2008; Peters et al., 2005). Opening of these channels produces an outward potassium current that functions as a ‘brake’ for neurons receiving persistent excitatory input (Greene and Hoshi, 2017). Consistently, mutations in KCNQ2/3 genes have been associated with seizures in the mouse (Singh et al., 2008), as well as in patients (Jentsch et al., 2000), pointing to these channels as interesting targets for anticonvulsant therapy (Barrese et al., 2018). To test whether neuro-MPC1-KO mice displayed an altered contribution of the M-type K+ conductance, we tested the effect of the M-type channel blocker XE991 (10 µM) on CA1 pyramidal cell firing. XE991 led to a significant increase in firing frequency of neuro-MPC1-WT cells, whereas firing of neuro-MPC1-KO cells was not significantly modified (Figure 5I and J). Consistently, XE991 induced a significant reduction in the rheobase and a shift in the threshold potential in neuro-MPC1-WT cells, but had no impact on neuro-MPC1-KO cells (Figure 5K and L), pointing to a limited activity of KCNQ2/3 channels in these neurons. Interestingly, bath application of βHB following KCNQ2/3 channel blockade with XE991 failed to reduce the hyperexcitability of neuro-MPC1-KO mice (Figure 5J–L). We also noticed that, in the absence of XE991, the reduction of intrinsic excitability by βHB in MPC-deficient neurons was accompanied by a significant increase in mAHP (Figure 5M, N), suggesting that βHB may potentiate the recruitment of the M-type K+ channels. Moreover, the M-type channel activator retigabine (10 µM) effectively decreased the hyperexcitability of pyramidal cells from neuro-MPC1-KO mice to a level that was no further affected by βHB (Figure 5O, P). This suggests that βHB and retigabine display a similar mechanism of action, which is consistent with recent findings showing that βHB can directly bind to and activate KCNQ2/3 channels (Manville et al., 2020).

We finally tested whether the increased neuronal excitability in neuro-MPC1-KO mice was also accompanied by alterations in glutamatergic transmission. In acute slices, we recorded field potentials in CA1 stratum radiatum elicited by electrical stimulation of the Schaffer collaterals (Figure 5—figure supplement 1L). No overt genotype differences were found in the input-output curves of field excitatory postsynaptic potentials (fEPSPs), and the lack of changes in paired-pulse ratio indicated no major alteration in the presynaptic release (Figure 5—figure supplement 1M, N).

Altogether, these results indicate that the hyperexcitability of CA1 pyramidal neurons from neuro-MPC1-KO mice is mediated by alterations in intrinsic cell excitability associated with a reduced M-type K+ channel activation, with no major changes in excitatory synaptic inputs.

Alteration of calcium homeostasis in MPC1-deficient neurons

The conductance of KCNQ channels is regulated by phosphatidylinositol-4,5-bisphosphate (PIP2) and calmodulin (CaM) (Alaimo and Villarroel, 2018; Gamper and Shapiro, 2003). In particular, reduction in free CaM in hippocampal neurons decreases M-current density and increases neuronal excitability (Shahidullah et al., 2005; Zhou et al., 2016). Thus, calcium could trigger loss of interaction of CaM and KCNQ2/3 channels, leading to M-type current suppression (Kosenko and Hoshi, 2013).

We tested whether disruption of calcium homeostasis could be responsible for the deficit in the M-type K+ channel activity displayed by MPC1-deficient neurons. We first assessed whether calcium homeostasis was perturbed in MPC-deficient cortical neurons in vitro. Using the fluorimetric calcium probes Fura2-AM and the low affinity FuraFF-AM combined with live cell imaging, we found a significant increase in the peak concentration of cytosolic calcium upon depolarization of both control and MPC-deficient neurons in response to either 10 μM glutamate (Figure 6A, B; Figure 6—figure supplement 1) or 50 mM KCl (Figure 6C–E). However, while the peak of calcium concentration was transient in control neurons, and returned to basal levels, both the magnitude and duration of the calcium elevation were greater in MPC-deficient neurons (Figure 6A and C). Interestingly, the long lasting increased calcium level in MPC-deficient neurons was abolished by addition of 10 mM βHB to the culture medium 30 min prior to recording (Figure 6A, B, Figure 6—figure supplement 1C). Together these results show that loss of MPC activity leads to a significant increase of cytosolic calcium levels in depolarized neurons.

Figure 6 with 3 supplements see all
Download asset Open asset
Defect in calcium homeostasis.

(A) Mean fluorescence signal intensity of cortical neurons loaded with Fura2-AM stimulated with 10 μM glutamate (dashed black arrow) prior the addition of ionomycin (red arrow) to reveal the neuronal calcium stock. (B) Graph showing the quantifications of control neurons, MPC-depleted neurons and MPC-depleted neurons+βHB showing an elevated level of cytosolic calcium in MPC-deficient stimulated neurons measured by Fura2-AM. N > 15 neurons per condition from three independent experiments. One-way ANOVA + Holm Sidak’s post-hoc test (shCtrl vs shMPC1 p = 0.0169, shMPC1 vs shMPC1+βHB p = 0.0001). (C) Mean fluorescence signal intensity of cortical neurons loaded with Fura2-AM before and after stimulation with 50 mM KCl (dashed black arrow) for 3 min. Neurons were then washed using a calcium-free medium. (D) Fluorescence signal intensity of control, MPC-deficient, and RU360-treated cortical neurons permeabilized with pluronic acid (0.02%). Neurons were loaded with Fura2-AM, stimulated with KCl 50 mM prior addition of fCCP to reveal the mitochondrial stocks of calcium. (E, F) Quantification of calcium increased upon depolarization (E) ratio of the fluorescence peak after adding KCl to the mean of the 10 first basal measurement) and the amount of mitochondrial calcium released by fCCP (F) ratio of the fluorescence peak after adding fCCP to the lowest point during wash in normal, MPC-deficient neurons and neurons + RU360. N > 13 neurons per condition from three independent experiments. One-way ANOVA + Holm Sidak’s post-hoc test ((E) Ctrl vs Zaprinast p < 0.0001, Ctrl vs RU360 p < 0.0001; (F) Ctrl vs Zaprinast p = 0.0003, Ctrl vs RU360 p < 0.0001). (G) Mitochondrial calcium measurement of AAV-infected cortical neurons expressing mtaequorin. The MCU was inhibited by RNA interference (shMCU), whereas the MPC was inhibited using the MPC inhibitor Zaprinast (5 μM). The bioluminescence values were converved into calcium concentrations according to Bonora et al. Two-way ANOVA + Holm-Sidak post-hoc test (No significant difference could be observed between groups in. basal conditions. shCtrl basal vs shCtrl KCl, p < 0.0001, shMCU basal vs shMCU KCl, p = 0.067, shCtrl+ Zaprinast basal vs shCtrl+ Zaprinast KCl, p = 0.0008, shMCU+ Zaprinast basal vs shMCU+ Zaprinast KCl, p = 0.99, shCtrl KCl vs shMCU KCl, p = 0.012, shCtrl KCl vs shCtrl+ Zaprinast KCl, p = 0.011. (H, I). Example traces and F-I relationship in WT cells with standard intracellular solution and with a solution containing the MCU inhibitor RU360 (one or 10 µM), which increased neuronal firing (10 µM: Two-way ANOVA, F(1, 72) = 26.03, p < 0.0001). (J, K) Lack of RU360 (10 µM) effect on neuronal firing in KO cells (Two-way ANOVA, F(1, 72) = 0.03607, p = 0.8499). (L) Example traces of WT cell firing elicited by a current ramp (300 pA max amplitude, APs are trimmed) in control condition and with RU360, with expanded portion at the bottom indicating mAHP measurement. (M) Summary graph of mAHP values in control condition and with RU360, indicating significant reduction in WT (unpaired t test, t = 2.352, p = 0.0392). (N, O) Example traces and F-I relationship in WT cells infused with RU360 (10 µM) and subsequently exposed to βHB (2 mM, > 20 min exposure), which decreased neuronal firing (Two-way ANOVA, F(1, 28) = 17.69, p = 0.0001) and augmented mAHP (inset, paired t test, t = 2.336, p = 0.0477). (P) Scheme of whole-cell recordings with an intracellular solution containing the calcium chelator BAPTA (10 mM), with representative voltage responses in WT and KO neurons. Cell firing was compared between the first 3 min after whole-cell establishment, after 15 min of recordings, and after subsequent bath-application of XE991 (10 µM). (Q) Average firing frequency elicited by the 3rd ramp of current injections, indicating no altered intrinsic excitability in WT cells upon diffusion of BAPTA into the cytoplasm, but increased firing by subsequent bath application of XE991 (One-way ANOVA, F(1.565, 12.52) = 8.29, p = 0.0074, Holm-Sidak’s multiple comparison *p < 0.05). In KO neurons, diffusion of BAPTA induced a significant decrease in cell firing, which was reversed by subsequent bath-application of XE991 (One-way ANOVA, F(1.553, 12.42) = 4.34, p = 0.0449, Holm-Sidak’s multiple comparison *p < 0.05). (R) Changes in firing frequency were accompanied by a tendency toward decreased rheobase in WT (One-way ANOVA, F(1.254, 10.03) = 8.05, p = 0.014, Holm-Sidak’s multiple comparison #p = 0.0512) and by significant changes in rheobase in KO neurons (One-way ANOVA, F(1.5, 12) = 7.974, p = 0.0093, Holm-Sidak’s multiple comparison *p < 0.5, **p < 0.01).

Mitochondria import calcium through the mitochondrial calcium uniporter (MCU) in a membrane potential dependent manner and thereby play a major role in calcium homeostasis (Giorgi et al., 2012). Given that the mitochondrial membrane potential of the MPC-deficient neurons was reduced (Figure 1C, F), we assessed whether the increased cytosolic calcium levels in MPC-deficient neurons could result from impaired calcium uptake by mitochondria, similar to what would be expected for reduced MCU activity. We monitored cytosolic calcium in cultured cortical neurons at rest or upon stimulation with 50 mM KCl, in the presence or absence of chemical inhibitors of the MPC. The MCU activity was downregulated either using the pharmacological inhibitor RU360 (Márta et al., 2021) or RNA interference (Figure 6—figure supplement 2A). These experiments showed that upon neuron depolarization with 50 mM KCl, the cytosolic calcium level was significantly higher in neurons in which MPC or MCU had been inactivated (Figure 6C–E; Figure 6—figure supplement 2B). The level of cytosolic calcium was not further increased when both MCU and MCP were inactivated concomitantly (Figure 6—figure supplement 2B-D). These results confirmed that impairing the MCU, similar to inhibiting the MPC, resulted in increased cytosolic calcium levels in depolarized neurons.

To pursue our investigations further, we used two strategies to assess mitochondrial calcium: (i) an indirect approach consisting in measuring the difference in the signal emitted by the cytosolic calcium probe, before and after depolarization of mitochondria with fCCP. Upon depolarization, mitochondria are expected to release their calcium content. (ii) a direct approach using the calcium luminescent probe aequorin targeted to mitochondria (Bonora et al., 2013; Tosatto et al., 2016). As expected, fCCP-induced mitochondrial uncoupling resulted in an increased signal from the cytosolic calcium probe in control neurons and in neurons with inactive MPC or MCU. However, the difference in signal intensity, before and after fCCP addition, was significantly attenutated in MPC and/or MCU-deficient neurons compared to control (Figure 6D,F; Figure 6—figure supplement 2B-D). These results suggested a decreased storage of calcium in mitochondria from MPC- and MCU-deficient neurons. The mitochondrial aequorin probe was then used to test whether this was the consequence of reduced intake of calcium by mitochondria from these neurons, upon activation. As expected, we found that upon neuronal depolarization with KCl, the chemiluminescence of aequorin increased significantly in control and MPC and/or MCU deficient neurons (Figure 6G). However, in cells lacking either MPC or MCU activity the aequorin signal was much lower compared to control and no additivity was found when both MPC and MPU were inactivated together (Figure 6G). Taken together, these results show that the increased cytosolic calcium in MPC and/or MCU-deficient neurons results, at least in part, from decreased import of calcium into mitochondria. The low mitochondrial membrane potential in MPC-deficient neurons most likely explains this result.

To further test whether the increased cytosolic calcium resulting from dysfunctional mitochondria was responsible for the hyperexcitability of MPC1-deficient neurons, we performed electrophysiological recordings in CA1 pyramidal cells in the presence of RU360 into the patch pipette. In neuro-MPC1-WT cells, addition of 1 µM or 10 µM RU360 to the cell pipette caused an increase in cell firing (Figure 6H,I) while 10 µM RU360 had no effect in neuro-MPC1-KO cells (Figure 6J,K). Importantly, blockade of the MCU with RU360 in neuro-MPC1-WT cells was accompanied by a significant reduction in the mAHP (Figure 6L,M), indicating that calcium alterations induced by mitochondrial dysfunction may indeed affect M-type K+ channel activation. Finally, although βHB treatment did not significantly alter the firing of neuro-MPC1-WT cells in control conditions (Figure 5E,F), it reduced the excitability of cells infused with 10 µM RU360 while slightly increasing mAHP (Figure 6N,O), consistent with the hypothesis that βHB normalizes the alteration in the M-type K + conductance.

To further substantiate the hypothesis that higher cytosolic calcium impairs M-type K+ channel activity in neuro-MPC1-KO cells, we performed patch-clamp experiments using an intracellular solution containing the calcium chelator BAPTA (10 mM). We compared cell firing between the first minutes after the establishment of the whole-cell condition and 15 min thereafter, that is before and after complete diffusion of BAPTA in the cytoplasm (Figure 6P–R). Whereas intrinsic excitability was unaltered in neuro-MPC1-WT cells at these two timepoints, neuro-MPC1-KO cells displayed significantly lower firing rate and higher rheobase upon calcium chelation (Figure 6Q,R). Notably, unlike in BAPTA-free recordings (Figure 5J,K,L), subsequent bath application of XE991 (10 µM) increased intrinsic excitability not only in neuro-MPC1-WT cells, but also in neuro-MPC1-KO cells, indicating that calcium chelation made available a contribution of M-type K+ channels that was otherwise impaired by the high intracellular calcium levels.

Altogether, our results show that MPC1-deficient neurons display a lower mitochondrial calcium buffering capacity which may explain the hypoactivity of the M-type K+ channel and the intrinsic hyperexcitability of neurons.

Discussion

Tight coupling between neuronal activity and energy metabolism is essential for normal brain function. Here, to assess the contribution of pyruvate metabolism in neuronal activity, we inactivated the MPC specifically in adult CamKIIα-expressing neurons in the mouse. As previously reported (Divakaruni et al., 2017; Grenell et al., 2019), we found that loss of the MPC led to decreased oxygen consumption and ATP production in glutamatergic neurons. Despite this, these mice appeared normal at rest and presented a normal behavioral repertoire (i.e. novelty exploration, sociability, stress coping), except for lower anxiety-like behaviors which are consistent with a higher glutamatergic tone (Cordero et al., 2016). Most strinkingly, however, these mice developed severe seizures immediately following low-level administration of two pro-convulsant drugs, the GABA receptor antagonist pentylenetetrazole (PTZ), or the glutamate receptor agonist kainic acid.

The lack of an apparent phenotype in neuro-MPC1-KO mice at rest suggests that, up to a certain point, mitochondria can compensate for the deficit in mitochondrial pyruvate import by using other substrates to fuel the TCA cycle. It seems unlikely that such a compensatory mechanism would involve β-oxidation of fatty acids since these neurons do not express the enzymes necessary for this process (Schönfeld and Reiser, 2013). Furthermore, it is unlikely that the astrocyte-neuron-shuttle, which supplies astrocyte-derived lactate to neurons to boost OXPHOS (Mächler et al., 2016), can circumvent the loss of the MPC since all available data thus far indicate that lactate must first be converted into pyruvate by neuronal LDH in order to fuel the TCA cycle. It has been recently reported that inactivation of the MPC in cultured neurons, using the MPC small molecule inhibitor UK5099 (Divakaruni et al., 2017), or MPC1 gene knockout in the developing retina specifically (Grenell et al., 2019), resulted in a switch in mitochondrial substrate metabolism leading to increased reliance on glutamate (Divakaruni et al., 2017) or in ketones (Grenell et al., 2019) to fuel energetics and anaplerosis. Furthermore, inactivation of the MPC in cultured neurons also increased oxidation of the branched chain keto-acid catabolites of leucine, isoleucine, and valine (Divakaruni et al., 2017). Whether oxidation of these substrates can circumvent decreased pyruvate oxidation to allow MPC-deficient neurons to sustain normal function in neuro-MPC1-KO mice at rest remains to be confirmed.

Despite the lack of an obvious phenotype in resting mice, we found that, when challenged with the pro-convulsant molecules PTZ or kainic acid, the neuro-MPC1-KO mice were far more sensitive than WT animals and rapidly exhibited severe acute seizures. This suggests that the basal electrical activity of MPC1-deficient neurons may be continuously counterbalanced by inhibitory synapses, providing the normal resting phenotype described above. However, upon release of the ‘brakes’ exerted by the inhibitory system, the neuro-MPC1-KO neurons would become hyperactive, which would translate into the observed epileptic output. Consistent with our data, mice deficient in pyruvate dehydrogenase (PDH), the enzyme acting immediately downstream of the MPC, were found to display an epileptiform cortical activity accompanied by behaviorally observable seizures (Jakkamsetti et al., 2019). In this case, the epileptiform activity occurred in the context of reduced background cortical activation and, as suggested by the authors, the most likely explanation was that seizures resulted from a combination of decreased activity of inhibitory neurons, mostly parvalbumin-expressing cortical neurons, with slightly overexcitable excitatory neurons. Similar to PDH-deficient neurons, we found that the MPC1-deficient neurons displayed higher input resistance and increased spike frequency after stimulation, a phenotype that we investigated further and found to be mediated by an impairment of the medium component of the after-hyperpolarization potential mediated by an M-type K + conductance.

K+ efflux is the primary force behind the cellular repolarization that limits the spike after depolarization and thereby prevents neuronal hyperexcitability. One important class of K+ channels that fulfills this task is the M-current (IM)-generating KCNQ channel family (also called Kv7 channels) (Wang et al., 1998). In hippocampal neurons the IM is mediated by the KCNQ2 and KCNQ3 channels (Kv7.1 and Kv7.2), which form hetero or homodimers. Loss of function of KCNQ2 or KCNQ3 causes epilepsy in humans and mice (Biervert et al., 1998; Schroeder et al., 1998; Singh et al., 2008; Watanabe et al., 2000). In support of the involvement of these channels in the intrinsic membrane hyperexcitability of MPC1-KO neurons, we found that their inhibition, using the small molecule XE991, did not change the electrical properties of KO neurons, while it made WT neurons more excitable. Our results suggest that KCNQ2/3 channels are closed in MPC1-deficient neurons, and that this could underlie their hyperexcitability.

Our observations point to dysregulation of calcium homeostasis as the cause for the silencing of these channels. High levels of cytosolic calcium have been reported to decrease KCNQ channel activity by detaching calmodulin from the channel or by inducing changes in the configuration of the calmodulin-KCNQ channel complex (Alaimo and Villarroel, 2018; Kosenko and Hoshi, 2013). In our study, we report a significant increase of cytosolic calcium levels in cultured depolarized MPC-deficient neurons due to an impaired capacity of mitochondria to import calcium. Accordingly, increasing cytosolic calcium levels in wild type neurons from acute hippocampal slices using the MCU inhibitor RU360 was sufficient to increase their firing properties, while RU360 had no significant effect on the excitability of the neuro-MPC1-KO neurons. Conversely, the intracellular calcium chelator BAPTA decreased intrinsic excitability in neuro-MPC1-KO neurons only and rendered them sensitive to XE991 blockade, suggesting that buffering the aberrant intracellular calcium levels was sufficient to reactivate the M-type K+ conductance and normalize the excitability of MPC1 deficient neurons. Altogether, these results argue in favour of mitochondrial-related calcium homeostasis dysregulation as the reason for the silencing of KCNQ2/3 channels in neuro-MPC1-KO neurons.

The ketogenic diet has been reported to decrease seizures in patients with pharmacologically refractory epilepsy (Carroll et al., 2019) and we now report that the hyperexcitability of neuro-MPC1-KO mice fed with ketones is significantly reduced. Several hypotheses have been proposed to explain how ketone bodies could reduce neuron excitability, some involving direct pharmacological effects while others argue for an indirect role as metabolic fuels (Yellen, 2008). Beta-hydroxybutyrate (βHB) has been previously reported to display a direct pharmacological effect on the M-channel (Manville et al., 2020) and its protective action against proconvulsant drugs in neuro-MPC1-KO mice could be at least explained by this mechanism. On the other hand, acetoacetate, which is unlikely to impact directly the M-channel, was as efficient as βHB in reducing PTZ-induced seizures in neuro-MPC1-KO mice. This, together with the ability of βHB to restore oxygen consumption, ATP production, and mitochondrial membrane potential in cultured MPC-deficient neurons, suggests that one of the main protective actions of ketone bodies in neuro-MPC1-KO mice may be through provision of acetyl-CoA to the TCA cycle. However, additional mechanisms cannot be excluded. It has been previously reported that decreased glycolysis induced by ketones bodies can trigger activation of KATP channels, thereby making neurons less excitable (Giménez-Cassina et al., 2012; Yellen, 2008). In our study, we show that MPC inhibition leads to increased aerobic glycolysis, which can be reversed by βHB. Whether KATP channels are involved in the protection conferred by ketones in neuro-MPC1-KO mice requires further investigations.

In conclusion, using mice carrying an inducible deletion of the MPC specifically in excitatory neurons, we have shown that, despite impaired pyruvate-mediated oxygen consumption and ATP production, glutamatergic neurons can sustain high firing and trigger severe behaviorally observable seizures when the GABAergic network is inhibited. Furthermore, our data provide an explanation for the paradoxical hyperactivity of excitatory neurons resulting from OXPHOS deficits, which often accompanies neuropathologies such as cerebral ischemia or diverse mitochondriopathies, and identify KCNQ channels as interesting therapeutic targets to prevent seizures occurring in these pathologies.

Materials and methods

Key resources table
Reagent type (species) or resourceDesignationSource or referenceIdentifiersAdditional information
Strain, strain background (Mouse, M. musculus)CamkIIaCreERT2 miceJackson laboratoryRRID:IMSR_JAX:012362
Strain, strain background (Mouse, M. musculus)Mpc1flox/flox micegift from Professor Eric TaylorNA
Strain, strain background (Mouse, M. musculus)Ai14 reporter micegift from Professor Ivan RodriguezNA
Strain, strain background (Mouse, M. musculus)GfapCreERT2gift from Professor Nicolas ToniNA
Strain, strain background (Mouse, M. musculus)Neuro-MPC1-KO (CamkIIaCreERT2 MPCflox/flox mice)This articleNASee materials and methods (p 18,19)
Strain, strain background (Mouse, M. musculus)Astro-MPC1-KO(GfapCreERT2 Mpcflox/flox mice)This articleNASee materials and methods (p 18,19)
Cell line (Homo sapiens)HEK293TATCCRRID: CVCL_0045
Biological sample (Mus musculus)Cultures of primary cortical neuronsThis article, Fauré et al., 2006See materials and methods (p 20)
Biological sample (Mus musculus)Organotypic cultures of hippocampusThis article, Marissal et al., 2018See Appendix 1
Biological sample (Mus musculus)Acute hippocampal slicesThis articleNASee materials and methods (p 19,20)
Recombinant DNA reagentPLKO.1_shMCUSigma Aldrich (NM_001033259)TRCN0000251263
Recombinant DNA reagentPLKO.1_shMPC1Sigma Aldrich (NM_016098)TRCN0000005485TRCN0000005487
Recombinant DNA reagentPLKO.1_shCTRLSigma Aldrich (SHC016)
Recombinant DNA reagentAAV-GCaMP6sUniversity of Pennsylvania Vector Core
Recombinant DNA reagentAde-mtaequorinGift from Rosario Rizzuto lab, Tosatto et al., 2016
Antibodyanti-MPC1 (rabbit)Sigma Aldrich(HPA045119)RRID:AB_109604211/2000 (WB)1/1000 (IF)1/250(IHC)
Antibodyanti-MPC2 (Mouse)Millipore (MABS1914)MABS19141/500 (WB)
Antibodyanti-bIII-tubulin (Mouse)Biolegend(801201)RRID:AB_23137731/5000 (WB)1/1000 (IF)
Antibodyanti-MCU (Rabbit)Sigma Aldrich (HPA 016480)RRID:AB_20718931/5000 (WB)
Antibodyanti-HSP70 (Mouse)Millipore (MABS1955)MABS19551/1000 (WB)
AntibodyAnti-TOMM20 (Rabbit)Abcam (Ab186735)RRID:AB_28899721/2000 (IF)
Antibodyanti-synaptophysin (Mouse)Abcam (ab8049)RRID:AB_21988541/2000 (WB)
Antibodyanti-Tyrosine Hydroxylase (Rabbit)Millipore (AB152)RRID:AB_3902041/2000 (WB)
Antibodyanti-CamKIIa (Goat)Abcam (ab87597)RRID:AB_20406771/5000 (WB)
Antibodyanti-GFAP (Mouse)Sigma Aldrich (G3893)RRID:AB_4770101/5000 (WB)
Antibodyanti-VDAC (Goat)Santa Cruz (sc-8829)RRID:AB_22148011/500 (WB)
Antibodyanti-bActin (Mouse)Sigma Aldrich (a3854)RRID:AB_2620111/50000 (WB)
Antibodygoat anti-mouse Alexa Fluor488Life technologies (A32723)RRID:AB_26332751/2000
Antibodygoat anti-rabbit Alexa Fluor594Life technologies (A11037)RRID:AB_25340951/2000
Antibodyanti-IgG-Mouse-HRPDako (P0447)RRID:AB_26171371/10000
Antibodyanti-IgG-Rabbit-HRPDako (P0217)RRID:AB_27287191/10000
Antibodyanti-IgG-Goat-HRPSanta Cruz (sc-2304)RRID:AB_6411581/10000
Commercial assay or kitCellTiter GloPromegaG9241
Commercial assay or kitDeadEnd Colorimetric TUNEL SystemPromegaG7130
Commercial assay or kitGlucoMen Lx Plus kitMenarini diagnostics
OtherKetogenic dietProvimi Kliba AGXL75:XP10
Chemical compound, drugFuraFFThermo Fisher ScientificF14181
Chemical compound, drugFura2-AMThermo Fisher ScientificF1221
Chemical compound, drugFluo4-AMThermo Fisher ScientificF14201
Chemical compound, drug2-NDBG (2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)–2-Deoxyglucose)Thermo Fisher ScientificN13195
Chemical compound, drugPentylenetetrazol (PTZ)Sigma AldrichP6500
Chemical compound, drugKainic AcidSigma AldrichK0250
Chemical compound, drugTamoxifenSigma Aldrich85,256
Software, algorithmPrism7Graphpad version 7.0 a, April 2, 2016.RRID:SCR_002798
OtherDigidata1550A digitizerMolecular Devices
OtherDigital Lynx SXNeuralynx, USA
OtherSeahorse XF 24 extracellular flux analyzerSeahorse Biosciences
OtherCytation 3TMBiotek Instrument Inc
OtherIX71 Olympus microscopeOlympus
OtherConfocal LSM780 microscopeZeiss

Study design

Request a detailed protocol

Data sources from mice included in vivo (behavioral tests, pro-convulsant drug injections, electroencephalogram), brain slice recordings of neuronal activity and electrophysiology, isolation of synaptosomes and primary culture of cortical neurons. For mouse experiments, pilot data from three or four samples per group provided an estimate of SD and effect magnitude, which, together with a power of 0.8 and P < 0.05, guided sample sizes using the G*power software (G*power version 3.1.9.6.). MPC1-WT and MPC1-KO mice from the same litter were randomly selected for experiments. Replicates and statistical tests are cited with each result. All procedures were approved by the Institutional Animal Care and Use Committee of the University of Geneva and with permission of the Geneva cantonal authorities. Data analysis was blind and performed concurrently on control and experimental data with the same parameters. No data, including outlier values, were excluded.

Mice

The CamkIIaCreERT2 mouse was obtained from Jackson (stock number 012362). The Mpc1flox/flox mouse was a gift from professor Eric Taylor (University of Iowa). The Ai14 reporter mouse was a gift from professor Ivan Rodriguez (University of Geneva). The GfapCreERT2 mouse was a gift from professor Nicolas Toni (University of Lausanne) (Gebara et al., 2016). By using the Cre driver lines, we generated two different cell-type specific Mpc1 KO mice: CamKIIaCreERT2-Mpc1flox/flox mice (here called neuro-MPC1-KO) in which Mpc1 was knocked out specifically in excitatory glutamatergic neurons; and GfapCreERT2-Mpc1flox/flox mice in which Mpc1 is knockout specifically is astrocytes (here called astro-MPC1-KO). In all experiments age-matched wild type controls were used and are referred to in the text as neuro-MPC1-WT (CamKIIaCreERT2-Mpc1flox/flox) and astro-MPC1-WT mice (GfapCreERT2-Mpc1flox/flox). The neuro-MPC1-KO and astro-MPC1-KO phenotypes were tamoxifen-inducible. In order to induce MPC1 deletion, the mice were injected intraperitoneally (ip) for five consecutive days with 100 μl of 10 mg/ml tamoxifen (Sigma, 85256) in sunflower oil. The mice were considered to be MPC1-KO from 1 week after the final injection. All experiments were carried out in accordance with the Institutional Animal Care and Use Committee of the University of Geneva and with permission of the Geneva cantonal authorities (Authorization numbers GE/42/17, GE/70/15, GE/123/16, GE/86/16, GE/77/18, GE/205/17) and of the Veterinary Office Committee for Animal Experimentation of Canton Vaud (Authorization number VD3081).

Pentylenetetrazol (PTZ)-induced convulsion protocol

Request a detailed protocol

We used the PTZ kindling model of epilepsy as described in Dhir, 2012. Briefly, this test entails chronic intraperitoneal (ip) injection of 35 mg/kg PTZ (Sigma, P6500), which is a sub-convulsant dose for WT mice, every 2 days for 2 weeks, and after each PTZ injection, the mice were scored according to their clinical symptoms, as described previously (Dhir, 2012; Mishra et al., 2018). After each PTZ injection, the animals were gently placed in isolated transparent plexiglass cages and their behavior was observed to assign a seizure score based on the following criteria: stage 1: sudden behavioral arrest and/or motionless staring; stage 2: jerks; stage 3: Straub’s tail (rigid tail being held perpendicularly to the surface of the body); stage 4: partial clonus in a sitting position; stage 5: generalized clonus; stage 6: convulsions including clonic and/or tonic–clonic seizures while lying on the side and/or wild jumping (convulsive status epilepticus). Mice were scored over a period of 30 min and the tests were performed in semi-blind mode (carried out by 2 experimenters of which only one knew the genotype). After the PTZ test, mice were immediately sacrificed in a CO2 chamber. The seizure severity score was calculated by taking the sum of the behavior and seizure patterns for all animals in a group and dividing by the number of animals present in the group.

Electroencephalogram (EEG)

Request a detailed protocol

Surface EEGs were recorded in head-fixed, awake animals with 32 stainless steel electrodes (500 µm Ø) covering the entire skull surface as described previously (Mégevand et al., 2008; Sheybani et al., 2018). Briefly, a head-post was placed under isoflurane anaesthesia allowing head-fixation. Recording sessions took place after a period of 4 days of head-fixation training to allow acclimatization of the animals to the experimental setup. PTZ was injected ip at the beginning of the session. Electrophysiological differential recordings were acquired with a Digital Lynx SX (Neuralynx, USA) at a sampling rate of 4 kHz and with a 2 kHz low-pass. The ground electrode was placed above the nasal bone and the reference electrode was placed on the midline between parietal bones (channel 31, Figure 3C). All signals were calculated against the average reference offline.

Patch-clamp electrophysiology

Request a detailed protocol

Tamoxifen-treated CamKIIaCreERT2-Mpc1flox/flox mice and wild-type littermates (6–10 weeks-old) were anaesthetized with isoflurane and decapitated, and the brain was quickly removed and placed in oxygenated (95% O2 / 5% CO2) ice-cold N-Methyl-D-glucamine (NMDG)-based medium, containing (in mM): 110 NMDG, 2.5 KCl, 1.2 NaH2PO4, 30 NaHCO3, 20 HEPES, 10 MgCl2, 0.5 CaCl2, 25 glucose, 5 L(+)-ascorbic acid, 2 thiourea, 3 Na-pyruvate (titrated to pH 7.2–7.3 with HCl). Acute hippocampal transverse slices (350 µm thick) were cut using a vibrating tissue slicer (Campden Instruments). Slices recovered for 1 hr at 35 °C and subsequently at room temperature in a storage solution containing (in mM): 92 NaCl, 2.5 KCl, 1.2 NaH2PO4, 30 NaHCO3, 20 HEPES, 2 MgCl2, 2 CaCl2, 25 glucose, 5 L(+)-ascorbic acid, 2 thiourea, 3 Na-pyruvate (titrated to pH 7.2–7.3 with NaOH). In the recording chamber, slices were superfused with oxygenated standard artificial cerebrospinal fluid (aCSF) containing (in mM): 130 NaCl, 25 NaHCO3, 2.5 KCl, 1.25 NaH2PO4, 1.2 MgCl2, 2 CaCl2, 18 glucose, 1.7 L(+)-ascorbic acid.

Whole-cell patch clamp recordings were performed at nearly physiological temperature (30°C–32°C), with borosilicate pipettes (3–4 MΩ) filled with (in mM): 130 KGluconate, 10 KCl, 10 HEPES, 10 phosphocreatine, 0.2 EGTA, 4 Mg-ATP, 0.2 Na-GTP (290–300 mOsm, pH 7.2–7.3). Whole-cell patch clamp recordings were performed at nearly physiological temperature (30°C–32°C), with borosilicate pipettes (3–4 MΩ) filled with (in mM): 130 KGluconate, 10 KCl, 10 HEPES, 10 phosphocreatine, 0.2 EGTA, 4 Mg-ATP, 0.2 Na-GTP (290–300 mOsm, pH 7.2–7.3).

For recordings with intracellular calcium chelation, pipettes (3–4 MΩ) were filled with (in mM): 100 KGluconate, 10 KCl, 10 HEPES, 10 phosphocreatine, 10 1,2-Bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid (BAPTA), 4 Mg-ATP, 0.2 Na-GTP (290–300 mOsm, pH 7.2–7.3). BAPTA was prepared in a 20 mM stock solution titrated with 50 mM KOH.

A control experimental series was conducted with narrow pipettes tips (9–10 MΩ) filled with (in mM): 130 KGluconate, 5 KCl, 10 HEPES, 5 Sucrose (275–280 mOsm, pH 7.2–7.3), in order to delay intracellular dialysis (Jakkamsetti et al., 2019) and minimize interference with intracellular ATP and Ca2+ levels. In this series, neuronal firing was measured within the first 1.5 min after whole-cell establishment (Figure 6—figure supplement 3).

To elicit neuronal firing, cells were held at –60 mV with direct current injections, and somatic current injections of increasing amplitude were provided using ramps of 5 s (six ramps with final amplitude ranging from 50 pA to 300 pA) or squared pulses of 2 s (25 pA delta increase, max amplitude 200 pA). Input resistance (Ri) was assessed by the passive current response to a –10 mV hyperpolarizing step while cells were held at –60 mV. In control condition, resting membrane potential (Vrmp) and neuronal firing were measured within the first 5 min from the establishment of the whole-cell condition. The rheobase and the firing threshold were measured as the level of current and voltage, respectively, that induced the first action potential in the ramp protocol. The effect of β-hydroxybutyrate (2 mM) was assessed after >20 min perfusion, and compared to cell firing prior to perfusion.

Signals were acquired through a Digidata1550A digitizer, amplified through a Multiclamp 700B amplifier, sampled at 20 kHz and filtered at 10 kHz using Clampex10 (Molecular Devices).

Cell culture and lentiviral transduction

Request a detailed protocol

Wild type pregnant mice were decapitated and E18 embryos were collected in HBSS medium. Primary cultures of cortical neurons were prepared as described previously (Fauré et al., 2006). Briefly, cortices were dissected from E18 mouse embryos in HBSS and treated with 0.25% trypsin-1mM EDTA for 15 min at 37 °C. Tissues were washed, transferred to DMEM seeding medium (DMEM, 10% horse serum, 0.5 mM L-glutamine) and dissociated by 7–8 cycles of aspiration and ejection through a micropipette tip. Neurons were seeded at 250,000 neurons per cm2 on coverslips coated with 50 μg/ml poly-D-lysine. After 3 hrs, the seeding medium was replaced by serum-free neuronal culture medium (Neurobasal medium, 2% B27 supplement, penicillin/streptomycin and 0.5 mM L-glutamine). For MCU downregulation 7 DIV neurons were treated with lentiviral particles containing shRNA targeting MCU (NM_001033259/TRCN0000251263; Sigma Aldrich) (Qiu et al., 2013) for a further 7–8 days. For MPC1 downregulation 7 DIV neurons were treated with lentiviral particles containing shRNA targeting MPC1 for a further 7–8 days. Briefly, to prepare viral particles, Hek293T cells were transfected with packaging and envelope expressing plasmids together with PLKO.1-shRNA control (SHC016, SIGMA) or targeting MPC1 with the following sequences: ShMPC1_1:CCGGGCTGCCTTACAAGTATTAAATCTCGAGATTTAATACTTGTAAGGCAGCTTTTT; ShMPC1_2:CCGGGCTGCCATCAATGATATGAAACTCGAGTTTCATATCATTGATGGCAGCTTTTT. After 72 hours the culture supernatant was collected, ultracentrifuged at 100,000 g for 2 hr.

Determination of oxygen consumption rate (OCR) and extracellular acidification rate (ECAR)

Request a detailed protocol

Measurement of oxygen consumption was performed using a Seahorse XF 24 extracellular flux analyzer (Seahorse Biosciences). A total of 80,000 cells were seeded in XF24 cell culture microplates and grown for 16 days. Measurement of basal and stimulation-dependent oxygen consumption was carried out at 37°C in aCSF (140 mM NaCl, 5 mM KCl, 1.2 mM KH2PO4, 1.3 mM MgCl2, 1.8 mM CaCl2, 5 mM Glucose, and 15 mM Hepes, pH 7.4). Cells were infected with control shRNA or shMPC1 as decribed above or treated with MPC1 inhibitors Zaprinast (Du et al., 2013), Rosiglitazone (Divakaruni et al., 2013), and UK5099 (Halestrap, 1975) at 5, 5, and 1 μM, respectively. Cells were treated as indicated in the figure legends for 30 min before performing the assay. Basal oxygen consumption was measured before injection. At the times indicated, the following compounds were injected: oligomycin (1 μM), fCCP (4 μM), Rotenone/Antimycin A (1 μM). Each measurement loop consisted of 30 s mixing, 2 min incubation, and 3 min measurement of oxygen consumption.

Determination of the extracellular acidification was carried out under the same conditions but in the absence of HEPES. The basal acidification rate was measured before injection. At the times indicated, the following compounds were injected: oligomycin (1 μM), 2-deoxyglucose (5 mM). Each measurement loop consisted of 2 min mixing, 2 min incubation, and 3 min measurement of oxygen consumption.

ATP measurements

Request a detailed protocol

ATP measurements were performed on 14–17 DIV neurons, infected with control or MPC1 shRNA as described above, or treated 30 min prior to performing the assay with MPC inhibitors. Neurons were washed and scraped in PBS. Neurons were centrigugated at 1000 rpm for 5 min and resuspended in 100 mL of CellTiter Glo reagent and agigated for 2 min to allow cell lysis. After 10 min incubation, luminescence was recorded.

Calcium imaging

E18.5 primary cortical neurons were isolated and seeded onto 35mm Fluorodishes or 96 well plate. Neurons were treated with control or MCU shRNAs at 7DIV and used for calcium imaging at 14–17 DIV.

Cytosolic calcium

Request a detailed protocol

Neurons were loaded with 5 μM FuraFF, Fura2-AM or Fluo4-AM (F14181, F1221, and F14201, Thermo Fisher Scientific) in recording buffer (150 mM NaCl, 4.25 mM KCl, 4 mM NaHCO3, 1.25 mM NaH2PO4, 1.2 mM CaCl2, 10 mM D-glucose, and 10 mM HEPES at pH 7.4) with 0.02% pluronic acid, at 37 °C and 5% CO2 for 30 min.

For FuraFF and Fura2, cells were washed and imaged in recording buffer using a custom-made imaging widefield system built on an IX71 Olympus microscope equipped with a 20×water objective. A Xenon arc lamp with a monochromator was used for excitation, exciting FuraFF or Fura2 fluorescence alternately at 340 nm ± 20 nm and 380 nm ± 20 nm and collecting emitted light through a dichroic T510lpxru or a 79003-ET Fura2/TRITC (Chroma), and a band-pass filter 535/30 nm. Neurons were stimulated using 50 mM KCl or 10 μM glutamate (G1626, Sigma) and 4 μM fCCP or 10 μM Ionomycin was added at the end of each time course experiment. Images were acquired using a Zyla CMOS camera (Andor) every 2–5 s. The images were then analysed using ImageJ. Briefly, Regions of Interest (ROIs) were selected and average fluorescence intensity was measured for each channel including the background fluorescence. After subtracting the background fluorescence, the ratio between 380 and 340nm was calculated and plotted as cytosolic [Ca2+] levels upon stimulation. The Mean amplitude was calculated for each cell using Graphpad Prism.

For Fluo4-AM, cells were washed and imaged using a fluorescent plate reader (Cytation 3TM, Biotek Instrument Inc) with the following parameters: Excitation/Emission: 485/515, Gain:115. Fluo4-AM fluorescence was recorded for 3 min prior and 5min after neuron depolarization with injection of 50mM KCl. Then fCCP (4μM) was added to unload mitochondria from their calcium content.

Mitochondrial calcium

Request a detailed protocol

For the quantification of mitochondrial calcium, neurons were infected with adenovirus allowing the expression of the mtaequorin wt (Bonora et al., 2013) 48 hr prior to imaging. Neurons were incubated with 5 μM coelenterazine for 3 hr in aCSF solution at RT. Luminescence emission was then recorded using a luminescent plate reader (Cytation 3TM, Biotek Instrument Inc) for 5 min prior to and after neuronal depolarization (50 mM KCl). The experiment was terminated by lysing the neurons with 100 μM digitonin in a hypotonic Ca2+-rich solution (10 mM CaCl2), thus discharging the remaining aequorin pool. The light signal was collected and calibrated into [Ca2+] values as previously described (Bonora et al., 2013).

Statistical analysis

Request a detailed protocol

The comparison of two groups was performed using a two-sided Student’s t-test or its non parametric correspondent, the Mann-Whitney test, if normality was not granted either because not checked (n < 10) or because rejected (D’Agostino and Pearson test). The comparisons of more than two groups were made using one or two ways ANOVAs followed by post-hoc tests, described in the figure legends, to identify all the significant group differences. N indicates independent biological replicates from distinct samples. Data are all represented as scatter or aligned dot plot with centre line as mean, except for western blot quantifications, which are represented as histogram bars. The graphs with error bars indicate 1 SEM (+/-) and the significance level is denoted as usual (#p < 0.1, *p < 0.05, **p < 0.01, ***p < 0.001). All the statistical analyses were performed using Prism7 (Graphpad version 7.0 a, April 2, 2016). version 7.0 a, April 2, 2016.

Appendix 1

Food and diet

Standard diet is composed of 4.9% fat, 24% crude proteins, 29% starch (Provimi Kliba AG, standard diet, 3800). The ketogenic diet (KD) is composed of 74.4% animal fat, 9.9% crude protein, 0.7% starch (Provimi Kliba AG, Ketogenic diet XL75:XP10).

Glycaemia and ketonemia measurements

Glycaemia and ketonemia were measured in blood using the GlucoMen Lx Plus kit (Menarini diagnostics) which has a sensitivity for ketones, mainly βHB, from 0.1 mM to 8 mM. If not stated otherwise, measurements were performed using one drop of blood from the tail-veins of mice fed ad-libitum.

Behavioural tests

In each behavioral test, 6–10 adult animals per group were analyzed. They were tested in two tests to evaluate their anxiety-like responses: the elevated plus maze (EPM) and open field (OF), followed by a sociability test and a test for stress coping behaviors, the forced swim test (FST), all described below. Testing took place with at least 5 days between paradigms. The EPM is a maze composed of two open and two closed arms (30 × 5 × 14 cm) separated by a central platform (5 × 5 cm). The mouse was introduced in the center of the maze facing the wall of the closed arm and allowed to explore freely for 5 min. The intensity of the lights was maintained at 12 lux on the open arms, 10 lux in the center and 4–3 lux in the closed. After each trial, the maze was cleaned with 5%–7% ethanol and dried. Video tracking of the animal’s location was performed by a camera placed above the arena. The percentage of time spent in the open arms, as a measure of anxiety, was calculated with Ethovision (Noldus SA) tracking system. The OF is an arena (50 × 50 cm) in which the experimental mouse is placed in one corner facing the wall and left to freely explore for 10 min. Lighting was maintained at 7 lux on the center. After each trial, the arena was cleaned with 5%–7% ethanol and dried. Video tracking of the animal was recorded by a camera fixed above the arena, and images were processed using the Ethovision tracking system. The percentage of time spent in the center of the open field was taken as an indicator of anxiety. In the Social preference (SP) test, the preference for either a social stimulus or an inanimate object is tested. The arena consists of a rectangular, three-chambered box with a center (20 × 35 x 35 cm) and two side compartments (30 × 35 x 35 cm) with sawdust covering the floor. Retractable doorways are located between the compartments to allow or prevent access to the side chambers. In both side chambers, an object (black dummy mouse) or a juvenile mouse C57BL/6 J (28 ± 2 days) are located in a wire cage (10.16 cm bottom diameter, 11 cm high, bars spaced 0.5 cm apart). Light conditions are kept at 10 lux in the center. Two consecutive days prior to testing, experimental animals were habituated to the apparatus for 10 min. Juvenile mice were also habituated to the wire cages for 30 min. In the test day, each experimental mouse was located in the center compartment with both doors closed for 5 min. The doors were then opened and the mouse was allowed to explore the arena for 10 min. Behavior was video-recorded and the percentage of time each mouse spent sniffing either the object or the juvenile scored with the Observer (Noldus SA) software. The Forced swim test (FST) involves placing each mouse in in a beaker containing 3 L of tempered water (24°C ± 1°C) for 6 min. Behavior was recorded with a video camera and the immobility time spent during the last 4 min quantified with the Ethovision (Noldus S.A.) tracking system.

Echo magnetic resonance (EchoMRI)

The body composition was measured with an echo magnetic resonance (Echo Medical System). Briefly, the mouse was weighed before scanning. To calibrate the device, the mouse weight was introduced and the animal was placed on the holder inside the scanner. The % of lean mass was calculated considering the total body weight of each animal.

lectrophysiological field recordings

Acute hippocampal slices were prepared as described in the main Materials and Methods section. Field recordings were conducted at nearly physiological temperature (30°C–32°C) in the presence of the GABAAR blocker picrotoxin (0.1 mM). Field excitatory postsynaptic potentials (fEPSPs) were acquired in CA1 stratum radiatum through a borosilicate pipette filled with aCSF while stimulating Schaffer collaterals (0.1ms duration) with a tungsten concentric microelectrode (World Precision Instruments). Input-output curves of fEPSPs were constructed by displaying the fEPSP initial slope as a function of the amplitude of the presynaptic volley (FV), which was increased by augmenting the stimulus intensity (50–500 µA). Two consequent stimuli were provided with an interval of 50ms. Paired-pulse ratio was calculated by dividing the initial slope of the second response by the initial slope of the first response.

Signals were acquired through a Digidata1550A digitizer, amplified through a Multiclamp 700B amplifier sampled at 4 kHz and filtered at 1 kHz for field recordings, using Clampex10 (Molecular Devices).

Calcium imaging of the network dynamics

Hippocampal slice cultures prepared as previously described (Marissal et al., 2018; Stoppini et al., 1991) were infected with virus to enable expression of the genetically encoded calcium sensor GCaMP6s under the control of the human synapsin promoter (University of Pennsylvania Vector Core). Slices were immersed in an artificial cerebro-spinal fluid containing 124 mM NaCl, 1.6 mM KCl, 1.2 mM KH2PO4, 1.3 mM MgCl2, 2.0 mM CaCl2 10 mM Glucose, and 2.0 mM ascorbic acid, pH 7.4, at room temperature (22 °C) and continuously perfused and oxygenated using a peristaltic pump. Calcium transients were recorded using a Nipkow-type spinning disk confocal microscope (Olympus) coupled with single-photon laser (excitation wavelength 488). Images were acquired through a CCD camera (Visitron Systems Evolve). Slices were imaged using a 10 × 0.30 NA objective (Olympus) at 8.9 Hz frame rate (i.e. 112ms per frame). Typically, imaging covered a field of 420 × 420 µm containing ~200 individual neurons in the CA1 area. For treatment with pentylenetetrazol (PTZ), slices were pre-incubated with 2 mM drug for 15 minutes, and, slices were imaged after addition of 50 µM carbachol (CCh), which induces the generation of activity patterns mimicking those recorded in vivo (Fisahn et al., 1998). All drugs remained present throughout the recordings.

Calcium data analyses were performed using the Matlab-based ‘Caltracer3beta’ software (Columbia University), and custom-made scripts as previously described (Marissal et al., 2018). This enabled (a) tracing of Regions Of Interests (ROIs) corresponding to the identified GCaMP6s-expressing neuronal soma, and (b) the calculation of the averaged fluorescence signal from each ROIs as a function of time. In order to distinguish the neuronal calcium activity from background activity (i.e. from nearby fibres), the fluorescence within a halo of the pixels surrounding the ROI was subtracted from the fluorescence signal recorded in the ROI. From the resulting signal, the onset and offsets of the calcium events were identified. Onsets were automatically detected when fluorescence in a given slice exceeded a threshold value (based on the background noise) for a minimum duration of 1 s (based on the kinetics of GCaMP6s), and offsets were defined as the half-decay time of the event. Onset and offsets were manually corrected after automatic detection, and used to estimate (1) the frequency, the amplitude, and the duration of the calcium events, and (2) the occurrence of co-activation (e.g. neuronal synchronization) exceeding random chance.

Isolation of synaptic membranes

Isolation of synaptic membranes (hereafter referred to as synaptosomes) from P70 neuro-MPC1-WT and neuro-MPC1-KO mice was performed according to Chassefeyre et al., 2015 with minor modifications. Briefly, cortices from one mouse were homogenized in 2 ml ice-cold isotonic lysis buffer (0.32 M sucrose, 4 mM Hepes pH 7.4, protease inhibitors) using a teflon-glass-homogenizer (10 strokes). The homogenate was centrifuged at 1,000 x g for 10 min to remove nuclei. The post-nuclear supernatant (S1) was spun down at 4 °C for 20 min at 13,800 x g, to yield crude synaptosomes (pellet P2) and crude cytosol (supernatant S2). The P2 fraction was homogenized in lysis buffer and layered onto discontinuous sucrose density gradients consisting of 3 ml each of 0.8 M, 1.0 M, 1.2 M sucrose in 4 mM Hepes, pH 7,4 containing protease inhibitors. The gradients were centrifuged at 82,500 x g in a Beckman SW41 rotor for 120 min and the synaptosomes were collected at the 1.0–1.2 M interface, resuspended in 5 vol. lysis buffer and spun down for 20 min at 150,000 g. The pelleted synaptosomes were resuspended in the appropriate buffer for either western blotting and oxygen consumption rate as described below under separate subheadings.

Determination of oxygen consumption rate (OCR) on synaptosome

Purified synaptosomes were resuspended in 140 mM NaCl, 5 mM KCl, 5 mM NaHCO3, 1 mM MgCl2, 1,2 mM Na2HP04, 10 mM D-glucose, 20 mM Hepes pH 7.4, and plated in XF24 cell culture microplates pre-coated with poly-D-lysine (100 μg/well). The plates were centrifuged at 3400 x g for 1 hour to ensure attachment of synaptosomes. Oxygen consumption was measured as for neurons (described in the main ‘Material and Method’ section), except that at the times indicated, the injected compounds were: oligomycin (2 μM), fCCP (4 μM), Rotenone/Antimycin A (1 μM), and each measurement loop consisted of 30 sec mixing, 2 min incubation, and 2 min measurement of oxygen consumption.

Glucose uptake

Glucose uptake measurements were performed on 15–17 DIV neurons, infected with shRNA against MPC1 or control shRNA as described above, and treated as indicated in the figure legends 30 minutes prior to performing the assay. Neurons were incubated with 2-NDBG (2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)–2-Deoxyglucose) in aCSF (described for the cell culture) containing 2 mM glucose for 15 min. After 5 min washing, live fluorescence (Ex 465 nm/ Em 540 nm) was quantified using Cytation three plate reader (BioTek Intruments).

Immunostaining

Immunostaining was performed according to De la Rossa et al., 2013 Briefly, neuro-MPC1-KO and neuro-MPC1-WT mice were perfused with 1 x PBS followed by 4% paraformaldehyde (PFA) in PBS and the brains where immediately post-fixed with 4% PFA at 4 °C overnight. Fixed brains were cut into 30 μm sections with a vibratome (Microm HM 650 V). The primary antibody was rabbit anti-MPC1 (Sigma, HPA045119, Anti-Brp44l); the secondary antibody was goat anti-rabbit Alexa Fluor (Life technologies, A11034) in presence of DAPI. Images were acquired using fluorescent (Zeiss Axiophot) or confocal (Zeiss LSM780) microscopy.

Determination of oxygen consumption rate (OCR) on synaptosomePurified synaptosomes were resuspended in 140 mM NaCl, 5 mM KCl, 5 mM NaHCO3, 1 mM MgCl2, 1,2 mM Na2HP04, 10 mM D-glucose, 20 mM Hepes pH 7.4, and plated in XF24 cell culture microplates pre-coated with poly-D-lysine (100 μg/well). The plates were centrifuged at 3400 x g for 1 hour to ensure attachment of synaptosomes. Oxygen consumption was measured as for neurons (described in the main ‘Material and Method’ section), except that at the times indicated, the injected compounds were: oligomycin (2 μM), fCCP (4 μM), Rotenone/Antimycin A (1 μM), and each measurement loop consisted of 30 sec mixing, 2 min incubation, and 2 min measurement of oxygen consumption.

Immunostaining was performed according to De la Rossa et al., 2013 Briefly, neuro-MPC1-KO and neuro-MPC1-WT mice were perfused with 1 x PBS followed by 4% paraformaldehyde (PFA) in PBS and the brains where immediately post-fixed with 4% PFA at 4 °C overnight. Fixed brains were cut into 30 μm sections with a vibratome (Microm HM 650 V). The primary antibody was rabbit anti-MPC1 (Sigma, HPA045119, Anti-Brp44l); the secondary antibody was goat anti-rabbit Alexa Fluor (Life technologies, A11034) in presence of DAPI. Images were acquired using fluorescent (Zeiss Axiophot) or confocal (Zeiss LSM780) microscopy.

The TUNEL assay was performed on fixed coronal sections using the DeadEnd Colorimetric TUNEL System (Promega, G7130) according to the manufacturer’s instructions. For in vitro immunostaining, 15 DIV control and neurons infected for 7 days with MPC1-targeting shRNA or control control shRNA, were washed in HBSS and fixed in PBS containing 4% PFA and 4% sucrose for 15 min. Neurons were incubated in 5% goat preimmune serum (GPi) diluted in 50 mM Tris pH7.4, 0.2% Tween20, for 20 min, then incubated in anti-βIII-tubulin (Mouse, Biolegend-801201) with anti-MPC1 or TOMM20 (Rabbit, ab186735, Abcam) and antibodies for 1 h at room temperature. After several washes in PBS, the sections were further incubated in PBS, 5% GPi, 0.2% Tween20 containing goat anti-rabbit Alexa Fluor594 (Life technologies, A11037) and goat anti-mouse Alexa Fluor488 (Life technologies, A32723) in presence of DAPI. Finally, sections were air-dried and mounted as above and images were acquired by confocal microscopy (Zeiss LSM780).

Western blotting

Cultured neurons, brain extracts or synaptosomes were homogenized in lysis buffer (50 mM Hepes, pH 7.4, 0.5% Triton X-100, protease inhibitors), and resolved by SDS-PAGE in 8% to 15% polyacrylamide gels. Proteins were electrotransferred to PVDF membranes. Membranes were blocked for 30 min in TBS containing 0.1% Tween20% and 5% milk powder. Primary antibodies were prepared in the same blocking solution and incubated with the membranes overnight at 4 °C. After three washes in TBS 0.1% Tween20, secondary HRP-coupled antibodies in blocking solution were added for 60 min with agitation at room temperature. After extensive washing, bound-antibodies were revealed using the ECL kit (Biorad). Antibodies used: anti-MPC1 (Rabbit, Sigma, HPA045119), anti-MPC2 (Mouse, Millipore, MABS1914), anti-MCU (Rabbit, Sigma, HPA 016480), anti-HSP70 (Mouse, Clone JG1, Millipore, MABS1955), anti-synaptophysin (Mouse, Abcam, ab8049), anti-Tyrosine Hydroxylase (Rabbit, Millipore, AB152), anti-CamKIIα (Goat, Abcam, ab87597), anti-GFAP (Mouse, Sigma, G3893), anti-VDAC (Goat, Santa Cruz, sc-8829), anti-Actin (Beta-actin-peroxidase, Sigma, a3854), anti-IgG-Rabbit-HRP (Dako, P0217), anti-IgG-Mouse-HRP Dako, P0447, anti-IgG-Goat-HRP (Santa Cruz, sc-2304).

Data availability

The data that are supporting the findings of this study are included within the article as source data files.

References

    1. Zhou X
    2. Zhuang F
    3. Li H
    4. Zheng K
    5. Hong Z
    6. Feng W
    7. Zhou W
    8. Chen J
    (2016)
    Calmodulin regulates KCNQ2 function in epilepsy
    American Journal of Translational Research 8:5610–5618.

Decision letter

  1. Gary Yellen
    Reviewing Editor; Harvard Medical School, United States
  2. Richard W Aldrich
    Senior Editor; The University of Texas at Austin, United States

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

[Editors' note: this paper was reviewed by Review Commons.]

https://doi.org/10.7554/eLife.72595.sa1

Author response

Reviewer #1 (Evidence, reproducibility and clarity (Required)):

The authors have presented a very interesting and compelling set of data regarding the impact of conditional deletion of the only known pathway allowing the uptake of pyruvate into mitochondria. The paper comprises two interwoven stories that are both important. The first is the remarkable finding that the majority of excitatory neurons in the cortex (i.e. those under the influence of the CaMKII promoter) show remarkable metabolic flexibility as they tolerate elimination of pyruvate oxidation, considered the major supplier of ATP in neurons. The data on this seem clear although the authors did not delve into the potential mechanisms of metabolic compensation that likely occurs. Instead they examined whether there was some mal-adaptive compensation and they found clear evidence of this: in the absence of MPC activity the mice are much more prone to epileptic seizures, unveiled experimentally by relatively standard protocols (kindling). The authors present largely very convincing evidence that this mal-adaptive compensation in turn ends up decreasing the activity of KV7.2/7.3 channels whose job is normally to limit runaway repetitive firing by mediating an hyperpolarizing K+ efflux following an action potential. This channel, put on the map as it was one of the downstream targets modulated by cholinergic metabotropic activation, is also know known to be controlled by Calmodulin and therefore cytosolic Ca levels. Overall, I think at its core this manuscript is interesting and important. There however several weaknesses, I fear, will diminish the impact on the eventual readership. If these points can be addressed, it will strengthen the longevity of these findings:

1) It is puzzling why the authors resorted to using shRNA-mediated KD of MPC1 for some of the in vitro studies when they have gone to the trouble of making a floxed CRE-dependent mouse. Primary cells (e.g. Figure 1) or organotypic cultures (Figure 6) from these mice would have made a more consistent set of starting conditions to compare data across the manuscript. As there viruses expressing the CRE recombinase are widely available this could have been used on mice simply harboring the floxed gene it they are worried about waiting for the expression of the CaMKII promoter for in-vitro conditions.

This is indeed a good point. We initially tried to use viruses expressing the CRE recombinase in cultured neurons from mice harboring the floxed gene as proposed by the reviewer. However, for reasons that we do not understand, the use of AAVs or lentiviruses expressing the CRE was found to be deleterious for the cultured neurons. In view of this toxicity we tried using TAT-CRE recombinase, a recombinant cell-permeant fusion recombinase, which we added directly to the medium. However, this strategy proved to be poorly efficient. We finally used cultures of Cre-floxed neurons in which we tried to knockout MPC1 gene using 4-hydroxytamoxifen in the culture medium. However, we did not obtain satisfying results because, as previously reported, cortical neurons grow poorly in the presence of 4-hydroxytamoxifen (Nichols et al., Cell Death and Disease, 2018. https://doi.org/10.1038/s41419-018-0607-9). For all these reasons we turned to the shRNA strategy and to the use of 3 small molecule inhibitors of the MPC each with different chemical structures. Both the RNA interference and the pharmacological approaches gave similar results, reinforcing our confidence in the specificity of the results, and the unlikelihood of off-target effects.

2) The data in Figure 5 gets a little less convincing as using extracellular glutamate to drive Ca elevations is so non-physiological that the results might really be distorted by the participation of something irrelevant to the story, even though it supports the overall interpretation for a role of Ca/CaM in the control of the channel. Similarly, the use of RU360 should be done with caution. The drug, although a useful antagonist of MCU in purified mitochondria, is famously finicky with respect to its ability to cross membranes and could well have off target impact. A much cleaner experiment would be to suppress the expression of MCU via KD. Presumably in the MPC-deficient neurons, this would have minimal impact on Ca signals. Given the frequent ambiguity associated with interpreting pharmacological results, coupled to the central importance of this finding in interpreting the entire paper, I think carrying out experiments with molecular genetic manipulation of MCU is warranted.

We thank the Reviewer for this valuable comment. Following their recommendation, we genetically downregulated the MCU using RNA interference. As shown in Figure 6 – Supplementary Figure 2A in the revised manuscript, we used a shRNA against MCU (Qiu et al., Nature Communications, 2013, doi:10.1038/ncomms3034), and were able to significantly downregulate the expression of the MCU by 66% in cultured cortical neurons.

We then measured cytosolic calcium levels using the Fluo4-AM probe and mitochondrial calcium levels either directly using mitochondria targeted aequorin as recommended by the Reviewer (see minor comment 2) or indirectly, by monitoring cytosolic calcium upon mitochondrial depolarization with the protonophore fCCP. Upon fCCP-induced mitochondrial depolarization, mitochondria release their calcium content.

Using high KCl concentration (50 mM), we found that cytosolic calcium increased significantly upon depolarization of cultured cortical neurons. However, the signal was significantly higher in the presence of the MPC inhibitor Zaprinast compared to control. Similar to MPC inhibition, downregulation of the MCU expression resulted in increased cytosolic calcium levels compared to control neurons. Combination of MCU and MPC inhibition did not result in higher levels of cytosolic calcium levels compared to separate inhibition of these two transporters. When mitochondria were depolarized using fCCP, cytosolic calcium augmented dramatically in control neurons, suggesting that a high amount of calcium had been taken up by mitochondria upon KCl-induced neuron excitation. In contrast, the level of calcium released by mitochondria from neurons treated with Zaprinast and/or from MCU-deficient neurons was significantly reduced compared to control neurons, suggesting a lower capacity of mitochondria from these neurons to take up calcium (see Figure 6 – Supplementary Figure 2B-D).

To further assess the capacity of mitochondria from MPC and/or MCU-deficient neurons to take up calcium upon neuron activation, we measured the bioluminescence emitted by mitochondria targeted aequorin. We found decreased bioluminescence levels in MPC and/or MCU deficient neurons exposed to KCl, confirming that mitochondria from these neurons show a deficit in calcium mitochondrial intake (see Figure 6G in the revised manuscript). These results likely explain that MPC-deficient neurons show abnormal elevated calcium levels in the cytosol upon stimulation.

These new results consolidate our previous findings using RU360 and support our hypothesis that the lower mitochondrial membrane potential of MPC-deficient neurons, as shown in our paper, is responsible for low calcium import by the MCU upon neuronal activation. This would explain, at least in part, the higher cytosolic calcium level in depolarized MPC- deficient neurons. High cytosolic calcium would reduce M-type channel activity, as previously published, and would explain the hyperactivation of neurons upon intense firing.

3) The authors have not really made clear in this paper whether the ability to suppress the phenotype of the MPC deficiency with ketones is really related to a providing TCA cycle support or instead a pharmacological impact on non-TCA related targets (such as the Kv7.2/7.3 channels). Presumably the use of other ketones might circumvent this. The action of ketone bodies has been a topic of considerable interest in neuroscience, given the clinical relevance for childhood epilepsies. Previous studies for example have argued for direct inhibition of the vesicular glutamate transporter (Juge et al. Neuron 2010). The use of other ketones (acetoacetate) would narrow down the interpretations of the data.

Our results point to 2 two possible mechanisms of 3-beta hydroxybutyrate: (i) providing acetyl-CoA to the Krebs cycle, thereby stimulating OXPHOS and (ii) direct action of 3-beta hydroxybutyrate on the activity of Kv7/7.3 channels. The reviewer is asking whether, in addition to 3-beta hydroxybutyrate, other ketone bodies, acetone or acetoacetate, may display antiepileptic activity, which would probably indicate that providing substrates to the TCA cycle is sufficient to prevent neuron-intrinsic hyperactivity and seizures. This is an interesting question, which we have now addressed.

We found that acetoacetate, 1% supplemented in the drinking water for one week before PTZ administration, was able to prevent the occurrence of seizures induced by PTZ (see Figure below). This result indicates that providing acetyl-CoA to mitochondria to fuel the TCA cycle and boost OXPHOS is sufficient to prevent the occurrence of seizures after PTZ administration. We thank the Reviewer for suggesting us this important experiment, which we have now added in the manuscript (Figure 4D).

Other:

1) In vitro – scramble controls only serve to demonstrate there is no general effect of treating cells with shRNAs, but do not address if there is an off-target effect. The most convincing thing here would be to have an shRNA-insensitive variant that rescues.

We have used 2 different shRNAs and 3 chemically unrelated inhibitors of the MPC and in all cases we obtained similar results. Therefore, we think that it is unlikely that the effects we observe are due to an off-target activity. The experiment proposed by the reviewer is interesting but extremely difficult. The idea would be to reintroduce a shRNA-insensitive MPC1 into MPC1-deficient neurons treated with shRNA. This is difficult as it is known that the expression level of MPC1 needs to be matched to that of MPC2, otherwise it leads to depolarization of the mitochondria. Obtaining the right level of MPC1 would be extremely difficult to achieve in practice.

2) Does rescuing CaMK binding to KCNQ channels rescue the phenotypes?

The question raised by the Reviewer implies that CaM is not constitutively bound to KCNQ channels, which is a matter of debate. As we pointed out in the discussion, ‘Intracellular calcium decreases CaM-mediated KCNQ channel activity (32, 36) by detaching CaM from the channel or by inducing changes in configuration of the calmodulin-KCNQ channel complex (36).’ The CaM-KCNQ tethering is also described in a review by Alaimo and Villaroel, 2018 (doi:10.3390/biom80300579): ‘[…] CaM was first defined as an integral subunit constitutively tethered to the C-terminal region of Kv7.2/3 channels since Kv7.2 mutants that were deficient in CaM binding were unable to generate measurable currents [5,21]. However, this model has been questioned since Kv7.2 channels, carrying a hB mutation [40] or Kv7.4 hA mutated channels [41] that do not bind CaM, can still reach the plasma membrane and are functional.’

When considering to manipulate CaM binding to KCNQ, it should also be considered that previous studies on this matter have been performed with heterologous systems and through genetic manipulations of CaM (by expression of a dominant negative or by overexpression of CaM) or of the KCNQ binding motif.

Based on both theoretical and practical issues, we, thus, believe that it is not feasible to implement a straightforward approach that would be compatible with our mouse model.

An alternative to this experiment was proposed by Reviewer #3, who recommended to use Ca2+ chelators in our electrophysiological experiments. This is the option we have chosen and we kindly ask the Reviewer to refer to point 1d raised by Reviewer 3.

3) As the authors imply that BHB activates KCNQ channels, showing this directly in their prep would provide some convincing data. If this is true, why doesn’t BHB increase firing rate of WT neurons?

Activation of KCNQ channels is expected to reduce (not increase) neuronal firing. When exposed to BHB, we indeed found that WT cells also show a trend towards decreased excitability (p=0.08). We report this trend now in the revised figure 5F. Given that KCNQ channels are already available to be recruited upon repetitive firing in WT cells (to a larger extent as compared to KO, as indicated by our data with XE991) it is conceivable that a further potentiating effect of BHB at the concentration used for ex vivo recordings (2 mM) will be limited.

4) How does the anti-epileptic effects of ketones in this study relate to previous reports of regulation of KATP channels? One of main concerns is that ketones might have a parallel anti-epileptic effect in the MPC1 KO mice that is unrelated to the mechanism proposed here.

The mechanisms by which ketones decrease neuron firing has been debated for several years and several mechanisms have been proposed, including inhibition of glycolysis and activation of ATP-sensitive potassium channels (KATP channels) as pointed out by the reviewer. We do not exclude at all the possibility that inhibition of the MPC could also have an impact on the KATP channels, especially because we observed that inhibition of the MPC activity leads to increased aerobic glycolysis, a process that is prevented by 3-beta hydroxybutyrate (Figure 1 of our paper). We have been investigating for quite a long time whether KATP channel activity was downregulated in MPC-deficient neurons and whether we could detect increased ATP near the plasma membrane. So far, we have not obtained convincing data showing a reduced activity of KATP channels in MPC-deficient neurons. These results however do not exclude the possibility that KATP channels, in addition to the M-channels, are involved in the hyperexcitability of MPC-deficient neurons and could be direct or indirect targets of ketones. This is now mentioned in the Discussion (line 460-478 p20):

“The ketogenic diet has been reported to decrease seizures in patients with pharmacologically refractory epilepsy (Carroll et al., 2019) and we now report that the hyperexcitability of neuro-MPC1-KO mice fed with ketones is significantly reduced. […] Whether KATP channels are involved in the protection conferred by ketones in neuro-MPC1-KO mice requires further investigations.”

Minor comments:

1. What is the MPC1 KO efficiency in CaMK neurons? The western blot in 2c is from the whole cortex and therefore does not show that.

As shown in figure 2C, MPC1 is significantly decreased in synaptosomes isolated from MPC1 KO cortices. This figure shows that these synaptosomes are highly enriched for CamKII and contain less astrocytic marker GFAP in comparison to the whole cortex.

2. Mitochondrial Ca2+ levels are not measured directly, for which there are many tools. This is needed to demonstrate definitively that there is a defect in Ca2+ handling."

The reviewer raises an important point and as mentioned above we have now used the mito-Aequorin, a luminescent quantitative probe targeted to mitochondria (M. Bonora et al., Subcellular calcium measurements in mammalian cells using jellyfish photoprotein aequorin-based probes. Nat Protoc 8, 2105-2118 (2013); A. Tosatto et al., The mitochondrial calcium uniporter regulates breast cancer progression via HIF-1alpha. EMBO Mol Med 8, 569-585 (2016)).

This is described above, in the response to Major point 2.

Reviewer #2 (Evidence, reproducibility and clarity (Required)):

De la Rossa and colleagues examined the consequences of conditionally knocking out MPC1,a subunit of the mitochondrial pyruvate carrier. They found that despite decreased levels of oxidative phosphorylation in excitatory neurons, phenotypically these conditional knockout mice were normal at rest. However, when challenged by inhibition of GABA neurotransmission, these animals developed severe seizure activity and expired. These authors then showed that neurons with an absence of MPC1 were hyperexcitable in part through abnormal calcium homeostasis, which was associated with a reduction in M-type inhibitory potassium channel activity. Intriguingly, the ketogenic diet and the major ketone body beta-hydroxybutyrate were able to reverse these changes.

This is a carefully conducted research study that reveals cell type-specific alterations of MPC1 deletion and functional consequences. The study design was logical and involved an exhaustive array of methodologies. The manuscript was generally well written and organized, and there are no major concerns. This study shows a direct causal relationship between impaired bioenergetics at the level of mitochondrial, and subsequent behavioral seizures, and is perhaps the most direct demonstration to date that an intrinsic disturbance of metabolic function can result in seizure activity (through changes in calcium regulation and impairment of ion channel activity). This will be an important contribution to the scientific literature.

Minor comments:

1. Page 4, line 86: Would recommend changing "paroxystic" to "paroxysmal" (the latter which is a more recognized term).

The change has been made and can be found in page 3 line 74 of the revised manuscript.

2. Page 5, line 124: recommend including the concentration of beta-hydroxybutyrate used when first mentioned. In general, concentration and dose information were difficult to find, as well as route of administration (for kainate, page 7, line 175). This type of information was not conveniently presented.

We have added this information, as recommended by the Reviewer. See line 169 (p7) for Kainic acid and line 118 (p5) for BHB.

3. Page 5, line 128: “both overcomed” is awkward. Would recommend using “both reversed”.

The change has been made. See line 123 (p6) of the revised manuscript.

4. Page 8, line 193: the authors probably meant "astro-MPC1-WT mice", not "neuro-MPC1-WT mice".

The controls in these experiments were neuro-MPC1-WT mice.

5. Page 12, lines 280-282: the authors might want to mention that chronic exposure of BHB might reduce the hyperexcitability of neuro-MPC1-KO mice.

We have hesitated in introducing this comment in the revised manuscript given that the mice were fed a maximum of 7 days with a ketogenic diet and we were not sure that this could be considered a chronic exposure.

6. Please review entire manuscript and use consistent tense. For example, on page 13, line 309, to maintain the past tense, it should read “We first assessed whether.”"

We checked the entire text and tried to use consistent tense.

7. Page 13, line 318: the authors used 10 mM BHB when examining calcium levels, but they earlier used 2 mM. They need to explain why they used a different concentration; and 2 vs 10 mM are quite different.

The reviewer makes a valid point. When we performed the in vitro experiments, we used 10 mM BHB, which is slightly higher than the amount of ketone bodies measured in the blood of mice fed on a ketogenic diet for 2 days (Supplementary figure 4). This concentration of BHB has also been used in other studies (see for example: Izumi et al., JCI 1998, 101:1121-1132). Later on, when electrophysiology experiments were performed, the person in charge of these experiments followed a previously published protocol by Yellen and colleagues, in which the authors had used 2 mM BHB (Ma et al., J. Neurosci 2007,27: 3618-3625). This explains the differences between the concentrations used in vitro and in vivo. The reference of Ma et al. was added lines 238-239, page 10 of the revised manuscript.

8. Page 13, line 323: it is not necessary to say “……interesting study published during the preparation of this manuscript." This phrase should be deleted, and the relevant reference simply cited.

We now removed this sentence

9. The authors need to explain more clearly in the beginning what exactly is meant by "paradoxical" hyperactivity. They provide greater meaning later in the manuscript, but this should be clarified at the outset.

We have explained what we mean by ‘paradoxical’ in the Introduction, line 72 (p3), page 3, and removed paradoxical from the abstract.

Reviewer #3 (Evidence, reproducibility and clarity (Required)):

2(MPC) in regulation of neuronal excitability. The authors find that MPC deficiency in glutamatergic neurons is associated with aerobic glycolysis, inhibition of the M-type K channels, and neuronal hyperexcitability that manifests in increased sensitivity to chemical pro-convulsants without changes in resting conditions. Alterations in Ca homeostasis in MPC-deficient neurons is consistent with reduced mitochondrial membrane potential and attendant diminution of mitochondrial calcium buffering capacity. The authors further show that the effect of MPC deficiency can be phenocopied by treatment of wild type neurons with a chemical inhibitor of the mitochondrial Ca uniporter (MCU). Based on these data, it is proposed that reduced mitochondrial Ca uptake causes neuronal hyperexcitability in the absence of MPC. Overall, the manuscript presents detailed electrophysiology and in vivo seizure studies. However, there is significant disconnect between the actual data in Figure 6 and the authors’ conclusions/proposed mechanism. In particular, the evidence for the role of Ca in the hyperexcitability due to MPC deficiency is the weak link in the authors’ argument.

1. The studies linking reduced mitochondrial Ca uptake to hyperexcitability in MPC-deficient neurons (Figure 6) have several limitations that significantly weaken the paper:

1a. The Ca measurements in cortical neurons (Figure 6A-F) are performed under conditions (glutamate/KCl) that are fundamentally different from those used in electrophysiology of CA1 pyramidal neurons (Figure 6G-N). The electrophysiological excitation is much briefer and less extreme than the chemical stimulation, and it is not clear that the Ca dysregulation occurs at the earliest times (see Figure 6A).

The use of glutamate/KCl to depolarize cultured neurons has been very useful to unmask a defect in calcium import into MPC-deficient mitochondria. This point is crucial and has now been consolidated with new experiments performed using downregulation of the MCU and the use of mitochondria targeted aequorin. However, we agree that this does not answer the key question raised by the Reviewer: does calcium dysregulation occur at the earliest time and does this play a role in neuron hyperexcitability? In Comment 1d, the Reviewer asked to question the role of calcium using a calcium chelator in the electrophysiological experiments. This is an important comment, which we have now addressed as detailed below under point 1d. These new results clearly establish an importance of calcium as a key factor in the hyperexcitability of MPC-deficient neurons and strongly suggest that calcium dysregulation initiates this process.

1b. The conclusion that MCU is functionally responsible for MPC’s effect on neuronal excitability is singularly based on the use of RU360 as a chemical inhibitor of MCU but the specificity of this reagent is questionable. Evidence for a cause and effect relationship that directly implicates altered MCU/mitochondrial Ca buffering has not been provided.

We thank the Reviewer for this valuable comment, which was also mentioned by Reviewer1. Following their recommendation, we genetically downregulated the MCU using RNA interference. As shown in Figure 6 – Supplementary Figure 2A of the revised manuscript, we used a shRNA against MCU (Qiu et al., Nature Communications, 2013, doi:10.1038/ncomms3034), and were able to significantly downregulate the expression of the MCU by 66% in cultured cortical neurons.

We then measured cytosolic calcium levels using the Fluo4-AM probe and mitochondrial calcium levels either directly using mitochondria targeted aequorin as recommended by the Reviewer (see minor comment 2) or indirectly, by monitoring cytosolic calcium upon mitochondrial depolarization with the protonophore fCCP. Upon fCCP-induced mitochondrial depolarization, mitochondria release their calcium content.

Using high KCl concentration (50 mM), we found that cytosolic calcium increased significantly upon depolarization of cultured cortical neurons. However, the signal was significantly higher in the presence of the MPC inhibitor Zaprinast compared to control. Similar to MPC inhibition, downregulation of the MCU expression resulted in increased cytosolic calcium levels compared to control neurons. Combination of MCU and MPC inhibition did not result in higher levels of cytosolic calcium levels compared to separate inhibition of these two transporters. When mitochondria were depolarized using fCCP, cytosolic calcium augmented dramatically in control neurons, suggesting that a high amount of calcium had been taken up by mitochondria upon KCl-induced neuron excitation. In contrast, the level of calcium released by mitochondria from neurons treated with Zaprinast and/or from MCU-deficient neurons was significantly reduced compared to control neurons, suggesting a lower capacity of mitochondria from these neurons to take up calcium (see Figure 6 – Supplementary Figure 2B-D).

To further assess the capacity of mitochondria from MPC and/or MCU-deficient neurons to take up calcium upon neuron activation, we measured the bioluminescence emitted by mitochondria targeted aequorin. We found decreased bioluminescence levels in MPC and/or MCU deficient neurons exposed to KCl, confirming that mitochondria from these neurons show a deficit in calcium mitochondrial intake (see Figure 6G in the revised manuscript). These results likely explain that MPC-deficient neurons show abnormal elevated calcium levels in the cytosol upon stimulation.

These new results consolidate our previous findings using RU360 and support our hypothesis that the lower mitochondrial membrane potential of MPC-deficient neurons, as shown in our paper, is responsible for low calcium import by the MCU upon neuronal activation. This would explain, at least in part, the higher cytosolic calcium level in depolarized MPC- deficient neurons. High cytosolic calcium would reduce M-type channel activity, as previously published, and would explain the hyperactivation of neurons upon intense firing.

1c. There is a large variation in the effect of 10 μm RU360 on firing frequency, comparing Figure 6H and N (blue traces), including the shape of the traces and values at ramp number 6. This calls into question the reliability of the comparisons in each separate figure.

Author response image 1
Download asset Open asset

Data presented in each single graph in the main Figures were obtained from groups of littermates through recordings conducted in consecutive days. Some caution is warranted when comparing data between different figures (i.e. between different experimental series), as several factors may contribute to inter-experiment variability, including variability between different batches of animals. However, the difference pointed out by the reviewer regarding the values of cell firing reported in Figure 6I and O is only apparent. When applying depolarizations with ramps of 5s, a fair amount of WT cells infused with RU-360 show high instantaneous firing frequency, especially for the last ramps that steeply reach high current levels. This leads to accommodation/inactivation of the action potential towards the end of the ramps, as shown in the example trace in Figure 6H. As a result, the current-frequency plot deviates from linearity, as it is the case in Figure 6I (blue trace) and, even more evidently, in Figure 6O. We have now reanalyzed the same recordings from WT cells infused with 10 µM RU-360 and measured the firing frequency in response to a square depolarizing step (250 pA) of 0.5 or 1 second. No difference was found between the firing frequencies of the cells from Figure 6I and Figure 6O (group 1 and group 2, respectively, in Author response image 1). Although the ramps may lead to some distortion for higher stimulation levels, we have decided to show results from ramps consistently throughout the main figures because this protocol with continuously increasing currents allows us to measure more precisely the rheobase and the firing threshold (as opposed to the stepwise increments of a square stimulation).

1d. The calcium > PIP2 > M-type K+ channel axis is well established but has not been fully explored in the context of MPC deficiency. The use of a calcium chelator will likely be informative in this context, and would be better evidence for a role of Ca in the MPC effects.

We would like to thank the Reviewer for this useful comment and suggestion. As recommended, we used a calcium chelator to further substantiate the hypothesis that higher cytosolic calcium impairs M-type K+ channel activity in neuro-MPC1-KO cells. We performed patch-clamp experiments using an intracellular solution containing the calcium chelator BAPTA (10 mM). We compared cell firing between the first minutes after the establishment of the whole-cell condition and 15 minutes thereafter, i.e. before and after complete diffusion of BAPTA in the cytoplasm. Whereas intrinsic excitability was unaltered in neuro-MPC1-WT cells at these two timepoints, neuro-MPC1-KO cells displayed significantly lower firing rate and higher rheobase upon calcium chelation (Figure 6P-R of the revised manuscript). Notably, unlike in BAPTA-free recordings (Figure 5J-L), subsequent bath application of XE991 (10 µM) increased intrinsic excitability not only in neuro-MPC1-WT cells, but also in neuro-MPC1-KO cells, indicating that calcium chelation made available a contribution of M-type K+ channels that was otherwise impaired by the high intracellular calcium levels (cf. Figure 5J-L).

1e. The ability of BHB to rescue various parameters in this and other figures in the paper is interesting but does not directly speak to the specific mechanism as to how MPC deficiency affects neuronal excitability. BHB’s effect is consistent with the metabolic flexibility of neurons when the TCA cycle cannot be fueled by glucose/pyruvate (as in GLUT1 or MPC deficiency).

In response to comment 3 of Reviewer 1, we have tested whether another ketone body, acetoacetate, could prevent PTZ-induced seizures in MPC-deficient animals. We found that this is the case (see Figure 4D in the revised manuscript). Given that this ketone body is not expected to directly bind the M channel, the most likely hypothesis as to how ketone bodies prevent PTZ-induced seizures in MPC KO neurons is through fueling the TCA cycle with acetyl-CoA and boosting OXPHOS.

Our hypotheses regarding the mechanism by which MPC deficiency affects neuronal excitability and ketones prevent this is as follows:

The MPC allows mitochondria to use pyruvate as a substrate for respiration and ATP production through OXPHOS. Its absence leads to decreased oxygen consumption and ATP production as shown by us and Divakaruni et al. (JCB, 2017). Furthermore, we show here that mitochondria display a lower mitochondrial membrane potential and a decreased capacity to import calcium. Upon intense firing, cytosolic calcium would increase, impairing the activity of M channels, and resulting in increased excitability. We show that ketones boost OXPHOS, prevent increased cytosolic calcium and thereby maintain M channels functional.

This mechanism does not exclude other mechanisms as it is likely that the effects of ketones are probably multifunctional. In particular, given that we observed increased glucose uptake in MPC-deficient neurons (Figure 1) and that ketones prevent this (Figure 1), as other groups before us (i.e. the labs of Garry Yellen and of Nika Danial) have shown, we have thought about the involvement of KATP channels. We have been investigating for quite a long time whether KATP channel activity was downregulated in MPC-deficient neurons and whether we could detect increased ATP near the plasma membrane. So far, we have not been able to convincingly show a reduced activity of KATP channels in MPC-deficient neurons. These results however do not exclude the possibility that KATP channels, in addition to the M-channels, are involved in the hyperexcitability of MPC-deficient neurons and could be direct or indirect targets of ketones. This is now mentioned in the Discussion and reads as follows (line 460-478 p20):

“The ketogenic diet has been reported to decrease seizures in patients with pharmacologically refractory epilepsy (Carroll et al., 2019) and we now report that the hyperexcitability of neuro-MPC1-KO mice fed with ketones is significantly reduced. KATP[…] Whether KATP channels are involved in the protection conferred by ketones in neuro-MPC1-KO mice requires further investigations.”

2. The manuscript (and the field) will benefit from a more scholarly discussion and integration of published literature:

We have modified the Discussion. All changes are in red and added some essential references.

2a. The published studies on the outcome of pharmacologic MPC inhibition in neurons (Ref 18, Divakaruni et al.) are not only consistent with the bioenergetic effect in Figure 1, but more importantly, show that interference with MPC does not lead to broad deficiencies in energy metabolism but rather remodel fuel utilization patterns to alternative substrates that feed the TCA cycle (BHB, leucine, etc). For this reason, terms such as “mitochondrial dysfunction” and “OXPHOS deficiency” used throughout the manuscript to describe MPC deficiency are vague and imprecise. In addition, this metabolic flexibility may explain lack of defects under resting conditions. In light of these considerations, the argument as to whether aerobic glycolysis in MPC-deficient neurons explains the lack of phenotype in resting conditions (p 17) seems one-sided. Overall, the studies in ref 18 are relevant to the current manuscript and should be better integrated in the discussion.

We agree with the Reviewer that the work of Divakaruni et al. provides an explanation for how, using glutamine oxidation, and possibly the branched chain keto-acid catabolites of leucine, isoleucine, and valine, neurons could compensate for mitochondrial pyruvate impairment, at least under resting conditions. These results are now mentioned in the Discussion as recommended by the Reviewer (see lines 396-413 p17-18) and we thank them for suggesting this very interesting hypothesis.

Regarding OXPHOS deficiency, as mentioned in the Divakaruni et al. paper, neurons lacking MPC activity show decreased maximal respiratory capacity and a drop in ATP levels, which, indeed, is consistent with our results (Figure 1). This is what we refer to OXPHOS deficiency throughout the text. However, to be more precise, when possible we replaced OXPHOS deficiency by drop in oxygen consumption and ATP production. So we agree that mitochondria with MPC impairment could, through metabolic flexibility, maintain a normal function under resting conditions, but on the other hand, when neurons are firing intensively, as is the case in the presence of PTZ, we think that mitochondria do not cope properly with the energetic demand and this, in part, results in a deficit in calcium intake.

2b. Several references are cited to describe the role of OXPHOS vis-à-vis aerobic glycolysis in neuronal function. At times, however, the authors’ statements are not consistent with what these papers actually show (or do not show). For example, see the use of refs 6 and 44 on p17 of the discussion, where the authors state that aerobic glycolysis uncoupled from OXPHOS is sufficient to provide ATP for normal neurotransmission, but this does not mean OXPHOS is not needed.

We thank the Reviewer for noting these inconsistencies. We have now removed these inappropriate references from the manuscript.

2c. Although the XE991 experiments support an important role for the M-type channels in the altered excitability with deficiency, it is not clear that the proposed mechanism can explain all of the electrophysiological differences, particularly those resting properties that are measured without a Ca challenge to the neurons. It would be good to discuss other possible mechanisms that could affect neuronal excitability.

Our results point to M-type channels as important players in the phenotype of the MPC-deficient mice. Previous reports indicate that inhibition of this channel by XE991 can modulate input resistance, membrane potential and firing threshold of pyramidal cells (e.g. Shah et al., 2018, doi/10.1073/pnas.0802805105; Hu et al. 2007, DOI:10.1523/JNEUROSCI.4463-06.2007; Petrovic et al., 2012, doi:10.1371/journal.pone.0030402). We also found that XE991 induced a shift towards more negative potentials in the firing threshold of WT cells, but not in MPC1 deficient cells (-3.3±0.6 vs. -0.4±1.0, n=9, 8, p=0.027). However, we agree with the reviewer that the phenotype is probably highly complex and that additional mechanisms may contribute to modulate the intrinsic excitability of MPC-deficient neurons. As recommended by the Reviewer, and as already mentioned above, additional mechanisms have been discussed in the Discussion from the revised manuscript.

https://doi.org/10.7554/eLife.72595.sa2

Article and author information

Author details

  1. Andres De La Rossa

    Department of Cell Biology, University of Geneva, Geneva, Switzerland
    Contribution
    Data curation, Data curation, Formal analysis, Methodology, Writing – original draft
    Contributed equally with
    Marine H Laporte and Simone Astori
    Competing interests
    No competing interests declared

  2. Marine H Laporte

    Department of Cell Biology, University of Geneva, Geneva, Switzerland
    Contribution
    Data curation, Data curation, Formal analysis, Validation, Writing – original draft, Writing – review and editing
    Contributed equally with
    Andres De La Rossa and Simone Astori
    For correspondence
    Marine.Laporte@unige.ch
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7856-6763

  3. Simone Astori

    Laboratory of Behavioral Genetics, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
    Contribution
    Data curation, Formal analysis, Writing – review and editing
    Contributed equally with
    Andres De La Rossa and Marine H Laporte
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7698-8332

  4. Thomas Marissal

    1. Institut de Neurobiologie de la Méditerranée (INMED), Université d'Aix- Marseille, Marseille cedex, France
    2. Department of Basic Neuroscience, University of Geneva., Geneva, Switzerland
    Contribution
    Data curation, Formal analysis
    Competing interests
    No competing interests declared

  5. Sylvie Montessuit

    Department of Cell Biology, University of Geneva, Geneva, Switzerland
    Contribution
    Data curation, Methodology
    Competing interests
    No competing interests declared

  6. Preethi Sheshadri

    Department of Cell and Developmental Biology, University College London, London, United Kingdom
    Contribution
    Formal analysis, Data curation
    Competing interests
    No competing interests declared

  7. Eva Ramos-Fernández

    Laboratory of Behavioral Genetics, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
    Contribution
    Data curation, Formal analysis
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3771-2189

  8. Pablo Mendez

    Cajal Institute, Madrid, Spain
    Contribution
    Data curation, Formal analysis
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9862-6818

  9. Abbas Khani

    Department of Basic Neuroscience, University of Geneva., Geneva, Switzerland
    Contribution
    Data curation, Formal analysis
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7324-4303

  10. Charles Quairiaux

    Department of Basic Neuroscience, University of Geneva., Geneva, Switzerland
    Contribution
    Supervision
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3770-8232

  11. Eric B Taylor

    Department of Biochemistry and Fraternal Order of Eagles Diabetes Research Center, Carver College of Medicine, University of Iowa, Iowa City, United States
    Contribution
    Resources
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4549-6567

  12. Jared Rutter

    Howard Hughes Medical Institute and Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, United States
    Contribution
    Resources
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2710-9765

  13. José Manuel Nunes

    Department of Genetic and Evolution, University of Geneva, Geneva, Switzerland
    Contribution
    Software, Validation
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7010-1382

  14. Alan Carleton

    Department of Basic Neuroscience, University of Geneva., Geneva, Switzerland
    Contribution
    Supervision
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5633-9159

  15. Michael R Duchen

    Department of Cell and Developmental Biology, University College London, London, United Kingdom
    Contribution
    Supervision
    Competing interests
    No competing interests declared

  16. Carmen Sandi

    Laboratory of Behavioral Genetics, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
    Contribution
    Supervision, Writing – original draft, Writing – review and editing
    For correspondence
    carmen.sandi@epfl.ch
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7713-8321

  17. Jean-Claude Martinou

    Department of Cell Biology, University of Geneva, Geneva, Switzerland
    Contribution
    Data curation, Funding acquisition, Supervision, Validation, Writing – original draft, Writing – review and editing
    For correspondence
    Jean-Claude.Martinou@unige.ch
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9847-2051

Funding

Ministerio de Economía, Industria y Competitividad, Gobierno de España (BFU2017-84490-P)

  • Pablo Mendez

Swiss National Science Foundation (31003A_179421/1 /1)

  • Jean-Claude Martinou

Kristian Gerhard Jebsen Foundation

  • Carmen Sandi
  • Jean-Claude Martinou

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

We would like to express our sincere thanks to Drs. Nika Danial (Harvard Medical School), Timothy Ryan (Weill Cornell Medicine), Garry Yellen (Harvard Medical School) and all members of the Martinou lab for helpful scientific discussion during the course of this work. We are also thankful to Denis Vecellio Reane from Rosario Rizzuto lab for sharing the Adenovirus-mtaequorin construct and for advices on mitochondrial calcium imaging. We also wish to extend our special thanks to Dr. Fabien Lanté and Prof. Anita Lüthi for advices on the electrophysiology experiments, to Dr. Kinsey Maundrell for help in reviewing the manuscript, to Professor Nicolas Toni (University of Lausanne) who kindly provided us with the GfapCreERT2 mouse, and to Professor Ivan Rodriguez (University of Geneva) who kindly provided us with the Ai14 reporter mouse.

Ethics

All experiments were carried out in accordance with the Institutional Animal Care and Use Committee of the University of Geneva and with permission of the Geneva cantonal authorities (Authorization numbers GE/42/17, GE/70/15, GE/123/16, GE/86/16, GE/77/18, GE/205/17) and of the Veterinary Office Committee for Animal Experimentation of Canton Vaud (Authorization number VD3081).

Senior Editor

  1. Richard W Aldrich, The University of Texas at Austin, United States

Reviewing Editor

  1. Gary Yellen, Harvard Medical School, United States

Publication history

  1. Preprint posted: December 22, 2020 (view preprint)
  2. Received: July 29, 2021
  3. Accepted: January 21, 2022
  4. Version of Record published: February 21, 2022 (version 1)
  5. Version of Record updated: February 22, 2022 (version 2)

Copyright

© 2022, De La Rossa et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,692
    Page views
  • 224
    Downloads
  • 8
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Andres De La Rossa
  2. Marine H Laporte
  3. Simone Astori
  4. Thomas Marissal
  5. Sylvie Montessuit
  6. Preethi Sheshadri
  7. Eva Ramos-Fernández
  8. Pablo Mendez
  9. Abbas Khani
  10. Charles Quairiaux
  11. Eric B Taylor
  12. Jared Rutter
  13. José Manuel Nunes
  14. Alan Carleton
  15. Michael R Duchen
  16. Carmen Sandi
  17. Jean-Claude Martinou
(2022)
Paradoxical neuronal hyperexcitability in a mouse model of mitochondrial pyruvate import deficiency
eLife 11:e72595.
https://doi.org/10.7554/eLife.72595

Categories and tags

Research organism

Further reading

    1. Computational and Systems Biology
    2. Neuroscience

    Multilayer brain networks can identify the epileptogenic zone and seizure dynamics

    Hossein Shahabi, Dileep R Nair, Richard M Leahy
    Research Article Updated

    Seizure generation, propagation, and termination occur through spatiotemporal brain networks. In this paper, we demonstrate the significance of large-scale brain interactions in high-frequency (80–200Hz) for the identification of the epileptogenic zone (EZ) and seizure evolution. To incorporate the continuity of neural dynamics, here we have modeled brain connectivity constructed from stereoelectroencephalography (SEEG) data during seizures using multilayer networks. After introducing a new measure of brain connectivity for temporal networks, named multilayer eigenvector centrality (mlEVC), we applied a consensus hierarchical clustering on the developed model to identify the EZ as a cluster of nodes with distinctive brain connectivity in the ictal period. Our algorithm could successfully predict electrodes inside the resected volume as EZ for 88% of participants, who all were seizure-free for at least 12 months after surgery. Our findings illustrated significant and unique desynchronization between EZ and the rest of the brain in the early to mid-seizure. We showed that aging and the duration of epilepsy intensify this desynchronization, which can be the outcome of abnormal neuroplasticity. Additionally, we illustrated that seizures evolve with various network topologies, confirming the existence of different epileptogenic networks in each patient. Our findings suggest not only the importance of early intervention in epilepsy but possible factors that correlate with disease severity. Moreover, by analyzing the propagation patterns of different seizures, we demonstrate the necessity of collecting sufficient data for identifying epileptogenic networks.

    1. Neuroscience

    Model-based whole-brain perturbational landscape of neurodegenerative diseases

    Yonatan Sanz Perl, Sol Fittipaldi ... Enzo Tagliazucchi
    Research Article

    The treatment of neurodegenerative diseases is hindered by lack of interventions capable of steering multimodal whole-brain dynamics towards patterns indicative of preserved brain health. To address this problem, we combined deep learning with a model capable of reproducing whole-brain functional connectivity in patients diagnosed with Alzheimer’s disease (AD) and behavioral variant frontotemporal dementia (bvFTD). These models included disease-specific atrophy maps as priors to modulate local parameters, revealing increased stability of hippocampal and insular dynamics as signatures of brain atrophy in AD and bvFTD, respectively. Using variational autoencoders, we visualized different pathologies and their severity as the evolution of trajectories in a low-dimensional latent space. Finally, we perturbed the model to reveal key AD- and bvFTD-specific regions to induce transitions from pathological to healthy brain states. Overall, we obtained novel insights on disease progression and control by means of external stimulation, while identifying dynamical mechanisms that underlie functional alterations in neurodegeneration.

    1. Neuroscience

    Distinct roles of forward and backward alpha-band waves in spatial visual attention

    Andrea Alamia, Lucie Terral ... Rufin VanRullen
    Research Article Updated

    Previous research has associated alpha-band [8–12 Hz] oscillations with inhibitory functions: for instance, several studies showed that visual attention increases alpha-band power in the hemisphere ipsilateral to the attended location. However, other studies demonstrated that alpha oscillations positively correlate with visual perception, hinting at different processes underlying their dynamics. Here, using an approach based on traveling waves, we demonstrate that there are two functionally distinct alpha-band oscillations propagating in different directions. We analyzed EEG recordings from three datasets of human participants performing a covert visual attention task (one new dataset with N = 16, two previously published datasets with N = 16 and N = 31). Participants were instructed to detect a brief target by covertly attending to the screen’s left or right side. Our analysis reveals two distinct processes: allocating attention to one hemifield increases top-down alpha-band waves propagating from frontal to occipital regions ipsilateral to the attended location, both with and without visual stimulation. These top-down oscillatory waves correlate positively with alpha-band power in frontal and occipital regions. Yet, different alpha-band waves propagate from occipital to frontal regions and contralateral to the attended location. Crucially, these forward waves were present only during visual stimulation, suggesting a separate mechanism related to visual processing. Together, these results reveal two distinct processes reflected by different propagation directions, demonstrating the importance of considering oscillations as traveling waves when characterizing their functional role.